


WEST Search History

DATE: Wednesday, September 08, 2004

Hide?	Set Name	Query	Hit Count
	<i>DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ</i>		
<input type="checkbox"/>	L17	L16 AND leukocyte	3
<input type="checkbox"/>	L16	colostrinin	26
<input type="checkbox"/>	L15	L14 AND colostrinin	2
<input type="checkbox"/>	L14	530/300,324,326,328,329.CCLS.	9116
<input type="checkbox"/>	L13	L12 AND colostrinin	4
<input type="checkbox"/>	L12	514/2,12,13,14,15,16,17.CCLS.	13935
<input type="checkbox"/>	L11	Georgiades.IN.	78
<input type="checkbox"/>	L10	Georgiades-J.IN.	7
<input type="checkbox"/>	L9	Georgiades-Jerzy.IN.	1
<input type="checkbox"/>	L8	Boldogh.IN.	10
<input type="checkbox"/>	L7	Boldogh-I.IN.	8
<input type="checkbox"/>	L6	Boldogh-Istvan.IN.	2
<input type="checkbox"/>	L5	Hughes.IN.	12356
<input type="checkbox"/>	L4	Hughes-T.IN.	39
<input type="checkbox"/>	L3	Hughes-Thomas.IN.	11
<input type="checkbox"/>	L2	Stanton.IN.	2977
<input type="checkbox"/>	L1	(Stanton-G.IN.)	6

END OF SEARCH HISTORY



Entrez PubMed Nucleotide Protein Genomes Structure OMIM PMC Journals Books

Search **PubMed** for **colostrinin** **Go** **Clear**

Limits Preview/Index History Clipboard Details

About Entrez

Text Version

Entrez PubMed

Overview
Help | FAQ
Tutorial
New/Noteworthy
E-Utilities

PubMed Services

Journals Database
MeSH Database
Single Citation Matcher
Batch Citation Matcher
Clinical Queries
LinkOut
Cubby

Related Resources

Order Documents
NLM Gateway
TOXNET
Consumer Health
Clinical Alerts
ClinicalTrials.gov
PubMed Central

Display **Summary** Show: **500** Sort **Send to** **Text**

Items 1-12 of 12 One page.

☐ **1:** Kruzel ML, Polanowski A, Wilusz T, Sokolowska A, Pacewicz M, Bednarz R, Georgiades JA. Related Articles, Links

The alcohol-induced conformational changes in casein micelles: a new challenge for the purification of colostrinin.
Protein J. 2004 Feb;23(2):127-33.
PMID: 15106878 [PubMed - in process]

☐ **2:** Bilikiewicz A, Gaus W. Related Articles, Links

Colostrinin (a naturally occurring, proline-rich, polypeptide mixture) in the treatment of Alzheimer's disease.
J Alzheimers Dis. 2004 Feb;6(1):17-26.
PMID: 15004324 [PubMed - in process]

☐ **3:** Mikulska JE, Lisowski J. Related Articles, Links

A proline-rich polypeptide complex (PRP) from ovine colostrum. Studies on the effect of PRP on nitric oxide (NO) production induced by LPS in THP-1 cells.
Immunopharmacol Immunotoxicol. 2003 Nov;25(4):645-54.
PMID: 14686804 [PubMed - indexed for MEDLINE]

☐ **4:** Boldogh I, Liebenenthal D, Hughes TK, Juelich TL, Georgiades JA, Kruzel ML, Stanton GJ. Related Articles, Links

Modulation of 4HNE-mediated signaling by proline-rich peptides from ovine colostrum.
J Mol Neurosci. 2003 Apr;20(2):125-34.
PMID: 12794306 [PubMed - indexed for MEDLINE]

☐ **5:** Leszek J, Inglot AD, Janusz M, Byczkiewicz F, Kiejna A, Georgiades J, Lisowski J. Related Articles, Links

Colostrinin proline-rich polypeptide complex from ovine colostrum--a long-term study of its efficacy in Alzheimer's disease.
Med Sci Monit. 2002 Oct;8(10):PI93-6.
PMID: 12388930 [PubMed - indexed for MEDLINE]

☐ **6:** Kruzel ML, Janusz M, Lisowski J, Fischleigh RV, Georgiades JA. Related Articles, Links


Towards an understanding of biological role of colostrinin peptides.
J Mol Neurosci. 2001 Dec;17(3):379-89.
PMID: 11859934 [PubMed - indexed for MEDLINE]


☐ **7:** Popik P. Related Articles, Links


Colostrinin and colostrinin-derived nonapeptide (colostral-val nonapeptide, CVNP) facilitate learning and memory in rats.
Pol J Pharmacol. 2001 Mar-Apr;53(2):166-8. No abstract available.
PMID: 11787957 [PubMed - indexed for MEDLINE]

☐ **8:** Popik P, Galoch Z, Janusz M, Lisowski J, Vetulani J. Related Articles, Links


Cognitive effects of Colostral-Val nonapeptide in aged rats.


 Behav Brain Res. 2001 Jan 29;118(2):201-8.
PMID: 11164518 [PubMed - indexed for MEDLINE]


 **9:** [Leszek J, Inglot AD, Janusz M, Lisowski J, Krukowska K, Georgiades JA.](#) [Related Articles, Links](#)

 Colostrinin: a proline-rich polypeptide (PRP) complex isolated from ovine colostrum for treatment of Alzheimer's disease. A double-blind, placebo-controlled study.
Arch Immunol Ther Exp (Warsz). 1999;47(6):377-85.
PMID: 10608295 [PubMed - indexed for MEDLINE]


 **10:** [Popik P, Bobula B, Janusz M, Lisowski J, Vetulani J.](#) [Related Articles, Links](#)

 Colostrinin, a polypeptide isolated from early milk, facilitates learning and memory in rats.
Pharmacol Biochem Behav. 1999 Sep;64(1):183-9.
PMID: 10495015 [PubMed - indexed for MEDLINE]

 **11:** [Sokal I, Janusz M, Miecznikowska H, Kupryszewski G, Lisowski J.](#) [Related Articles, Links](#)

 Effect of colostrinin, an immunomodulatory proline-rich polypeptide from ovine colostrum, on sialidase and beta-galactosidase activities in murine thymocytes.
Arch Immunol Ther Exp (Warsz). 1998;46(3):193-8.
PMID: 9704152 [PubMed - indexed for MEDLINE]


 **12:** [Inglot AD, Gelder F, Georgiades JA.](#) [Related Articles, Links](#)

 Tumor-associated antigens are cytokine inducers and hyporeactivity factors to the immune system.
Biotherapy. 1998;11(1):27-37.
PMID: 9617463 [PubMed - indexed for MEDLINE]

Display **Summary** Show: **500** **Sort** **Send to** **Text**

[Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)
[Department of Health & Human Services](#)
[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Aug 30 2004 06:52:01



Entrez PubMed Nucleotide Protein Genomes Structure OMIM PMC Journals Books

Search PubMed for PRP AND colostrum Go Clear

Limits Preview/Index History Clipboard Details

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Display Summary Show: 500 Sort Send to Text
Items 1-22 of 22 One page.

☐ 1: Mikulska JE, Lisowski J.

[Related Articles, Links](#)

A proline-rich polypeptide complex (PRP) from ovine colostrum. Studies on the effect of PRP on nitric oxide (NO) production induced by LPS in THP-1 cells.

Immunopharmacol Immunotoxicol. 2003 Nov;25(4):645-54.

PMID: 14686804 [PubMed - indexed for MEDLINE]

☐ 2: Leszek J, Inglot AD, Janusz M, Byczkiewicz F, Kiejna A, Georgiades J, Lisowski J.

[Related Articles, Links](#)

Colostrinin proline-rich polypeptide complex from ovine colostrum--a long-term study of its efficacy in Alzheimer's disease.

Med Sci Monit. 2002 Oct;8(10):PI93-6.

PMID: 12388930 [PubMed - indexed for MEDLINE]

☐ 3: Kruzel ML, Janusz M, Lisowski J, Fischleigh RV, Georgiades JA.

[Related Articles, Links](#)

Towards an understanding of biological role of colostrinin peptides.

J Mol Neurosci. 2001 Dec;17(3):379-89.

PMID: 11859934 [PubMed - indexed for MEDLINE]

☐ 4: Zablocka A, Janusz M, Rybka K, Wirkus-Romanowska I, Kupryszewski G, Lisowski J.

[Related Articles, Links](#)

Cytokine-inducing activity of a proline-rich polypeptide complex (PRP) from ovine colostrum and its active nonapeptide fragment analogs.

Eur Cytokine Netw. 2001 Jul-Sep;12(3):462-7.

PMID: 11566627 [PubMed - indexed for MEDLINE]

☐ 5: Leszek J, Inglot AD, Janusz M, Lisowski J, Krukowska K, Georgiades JA.

[Related Articles, Links](#)

Colostrinin: a proline-rich polypeptide (PRP) complex isolated from ovine colostrum for treatment of Alzheimer's disease. A double-blind, placebo-controlled study.

Arch Immunol Ther Exp (Warsz). 1999;47(6):377-85.

PMID: 10608295 [PubMed - indexed for MEDLINE]

☐ 6: Domaraczenko B, Janusz M, Orzechowska B, Jarosz W, Blach-Olszewska Z.

[Related Articles, Links](#)

Effect of proline rich polypeptide from ovine colostrum on virus replication in human placenta and amniotic membrane at term; possible role of endogenous tumour necrosis factor alpha.

Placenta. 1999 Nov;20(8):695-701.

PMID: 10527824 [PubMed - indexed for MEDLINE]


☐ 7: Orzechowska B, Janusz M, Domaraczenko B, Blach-Olszewska Z.


[Related Articles, Links](#)

Antiviral effect of proline-rich polypeptide in murine resident peritoneal cells.

Acta Virol. 1998 Apr;42(2):75-8.


PMID: 9770073 [PubMed - indexed for MEDLINE]

 **8:** [Sokal I, Janusz M, Miecznikowska H, Kupryszewski G, Lisowski J.](#) Related Articles, Links

 Effect of colostrinin, an immunomodulatory proline-rich polypeptide from ovine colostrum, on sialidase and beta-galactosidase activities in murine thymocytes.


Arch Immunol Ther Exp (Warsz). 1998;46(3):193-8.
PMID: 9704152 [PubMed - indexed for MEDLINE]

 **9:** [Blach-Olszewska Z, Janusz M.](#) Related Articles, Links

 Stimulatory effect of ovine colostrinine (a proline-rich polypeptide) on interferons and tumor necrosis factor production by murine resident peritoneal cells.


Arch Immunol Ther Exp (Warsz). 1997;45(1):43-7.
PMID: 9090439 [PubMed - indexed for MEDLINE]

 **10:** [Ingłot AD, Janusz M, Lisowski J.](#) Related Articles, Links

 Colostrinine: a proline-rich polypeptide from ovine colostrum is a modest cytokine inducer in human leukocytes.


Arch Immunol Ther Exp (Warsz). 1996;44(4):215-24.
PMID: 9017161 [PubMed - indexed for MEDLINE]

 **11:** [Janusz M, Błaszczyk B.](#) Related Articles, Links


 Effect of a proline-rich polypeptide on IgG level in Chickens.


Arch Immunol Ther Exp (Warsz). 1996;44(1):23-6.
PMID: 8874765 [PubMed - indexed for MEDLINE]

 **12:** [Janusz M, Lisowski J.](#) Related Articles, Links

 Proline-rich polypeptide (PRP)--an immunomodulatory peptide from ovine colostrum.


Arch Immunol Ther Exp (Warsz). 1993;41(5-6):275-9. Review.
PMID: 8010865 [PubMed - indexed for MEDLINE]

 **13:** [Siemion JZ, Folkers G, Szewczuk Z, Jankowski A, Kubik A, Voelter W.](#) Related Articles, Links


 Peptides related to the active fragment of "proline rich polypeptide", an immunoregulatory protein of the ovine colostrum. Spectroscopic and computer modeling studies.


Int J Pept Protein Res. 1990 Dec;36(6):506-14.
PMID: 2090642 [PubMed - indexed for MEDLINE]

 **14:** [Janusz M.](#) Related Articles, Links


 [Proline-rich-polypeptide from ovine colostrum (PRP): its structure and properties. II]


Postepy Hig Med Dosw. 1988 May-Jun;42(3):237-59. Review. Polish. No abstract available.
PMID: 3073376 [PubMed - indexed for MEDLINE]

 **15:** [Lisowski J, Wiecezorek Z, Janusz M, Zimecki M.](#) Related Articles, Links

 Proline-rich polypeptide (PRP) from ovine colostrum. Bi-directional modulation of binding of peanut agglutinin, resistance to hydrocortisone, and helper activity in murine thymocytes.



Arch Immunol Ther Exp (Warsz). 1988;36(4):381-93.
PMID: 2977937 [PubMed - indexed for MEDLINE]

 **16:** [Janusz M, Wiecezorek Z, Spiegel K, Kubik A, Szewczuk Z, Siemion I, Lisowski J.](#) Related Articles, Links

 Immunoregulatory properties of synthetic peptides, fragments of a proline-rich polypeptide (PRP) from ovine colostrum.



Mol Immunol. 1987 Oct;24(10):1029-31.

PMID: 3316989 [PubMed - indexed for MEDLINE]

 **17:** [Janusz M, Staroscik K, Zimecki M, Wieczorek Z, Lisowski J.](#) [Related Articles, Links](#) **A proline-rich polypeptide (PRP) with immunoregulatory properties isolated from ovine colostrum. Murine thymocytes have on their surface a receptor specific for PRP.**


Arch Immunol Ther Exp (Warsz). 1986;34(4):427-36.

PMID: 3026278 [PubMed - indexed for MEDLINE]

 **18:** [Staroscik K, Janusz M, Zimecki M, Wieczorek Z, Lisowski J.](#) [Related Articles, Links](#) **Immunologically active nonapeptide fragment of a proline-rich polypeptide from ovine colostrum: amino acid sequence and immunoregulatory properties.**



Mol Immunol. 1983 Dec;20(12):1277-82.

PMID: 6656774 [PubMed - indexed for MEDLINE]

 **19:** [Zimecki M, Janusz M, Staroscik K, Lisowski J, Wieczorek Z.](#) [Related Articles, Links](#) **Effect of proline-rich polypeptide on donor cells in graft-versus-host reaction.**


Immunology. 1982 Sep;47(1):141-7.

PMID: 6981586 [PubMed - indexed for MEDLINE]

 **20:** [Pichichero ME, Insel RA.](#) [Related Articles, Links](#) **Relationship between naturally occurring human mucosal and serum antibody to the capsular polysaccharide of Haemophilus influenzae type b.**



J Infect Dis. 1982 Aug;146(2):243-8.

PMID: 6980956 [PubMed - indexed for MEDLINE]

 **21:** [Zimecki M, Janusz M, Staroscik K, Wieczorek Z, Lisowski J.](#) [Related Articles, Links](#) **Immunological activity of a proline-rich polypeptide from ovine colostrum.**

Arch Immunol Ther Exp (Warsz). 1978;26(1-6):23-9.

PMID: 749775 [PubMed - indexed for MEDLINE]

 **22:** [Janusz M, Staroscik K, Zimecki M, Wieczorek Z, Lisowski J.](#) [Related Articles, Links](#) **Physicochemical properties of a proline-rich polypeptide (PRP) from ovine colostrum.**


Arch Immunol Ther Exp (Warsz). 1978;26(1-6):17-21.

PMID: 35126 [PubMed - indexed for MEDLINE]

Display	Summary	Show: 500	Sort	Send to	Text
---------	---------	-----------	------	---------	------

[Write to the Help Desk](#)[NCBI | NLM | NIH](#)[Department of Health & Human Services](#)[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Aug 30 2004 06:52:01



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books
 Search PubMed for NP AND colostrum Go Clear
 Limits Preview/Index History Clipboard Details

About Entrez

Text Version

Entrez PubMed

Overview
 Help | FAQ
 Tutorial
 New/Noteworthy
 E-Utilities

PubMed Services

Journals Database
 MeSH Database
 Single Citation Matcher
 Batch Citation Matcher
 Clinical Queries
 LinkOut
 Cubby

Related Resources

Order Documents
 NLM Gateway
 TOXNET
 Consumer Health
 Clinical Alerts
 ClinicalTrials.gov
 PubMed Central

Display Summary Show: 500 Sort Send to Text
 Items 1-7 of 7 One page.

☐ 1: [Mikulska JE, Lisowski J.](#) Related Articles, Links

A proline-rich polypeptide complex (PRP) from ovine colostrum. Studies on the effect of PRP on nitric oxide (NO) production induced by LPS in THP-1 cells.
 Immunopharmacol Immunotoxicol. 2003 Nov;25(4):645-54.
 PMID: 14686804 [PubMed - indexed for MEDLINE]

☐ 2: [Richt JA, Lager KM, Janke BH, Woods RD, Webster RG, Webby RJ.](#) Related Articles, Links

Pathogenic and antigenic properties of phylogenetically distinct reassortant H3N2 swine influenza viruses cocirculating in the United States.
 J Clin Microbiol. 2003 Jul;41(7):3198-205.
 PMID: 12843064 [PubMed - indexed for MEDLINE]

☐ 3: [Zablocka A, Janusz M, Rybka K, Wirkus-Romanowska I, Kupryszewski G, Lisowski J.](#) Related Articles, Links

Cytokine-inducing activity of a proline-rich polypeptide complex (PRP) from ovine colostrum and its active nonapeptide fragment analogs.
 Eur Cytokine Netw. 2001 Jul-Sep;12(3):462-7.
 PMID: 11566627 [PubMed - indexed for MEDLINE]

☐ 4: [Daniels JT, Hatfield PG, Burgess DE, Kott RW, Bowman JG.](#) Related Articles, Links

Evaluation of ewe and lamb immune response when ewes were supplemented with vitamin E.
 J Anim Sci. 2000 Oct;78(10):2731-6.
 PMID: 11048940 [PubMed - indexed for MEDLINE]

☐ 5: [Sokal J, Janusz M, Miecznikowska H, Kupryszewski G, Lisowski J.](#) Related Articles, Links

Effect of colostrinin, an immunomodulatory proline-rich polypeptide from ovine colostrum, on sialidase and beta-galactosidase activities in murine thymocytes.
 Arch Immunol Ther Exp (Warsz). 1998;46(3):193-8.
 PMID: 9704152 [PubMed - indexed for MEDLINE]

☐ 6: [Ingłot AD, Janusz M, Lisowski J.](#) Related Articles, Links

Colostrinine: a proline-rich polypeptide from ovine colostrum is a modest cytokine inducer in human leukocytes.
 Arch Immunol Ther Exp (Warsz). 1996;44(4):215-24.
 PMID: 9017161 [PubMed - indexed for MEDLINE]


☐ 7: [Hosomi O, Takeya A.](#) Related Articles, Links

Identification of a soluble UDP-Gal: Gal (beta 1-4)Glc (or GlcNAc) (alpha 1-3) galactosyltransferase of bovine colostrum.
 Nippon Juigaku Zasshi. 1989 Oct;51(5):961-8.
 PMID: 2514315 [PubMed - indexed for MEDLINE]

Display Summary Show: 500 Sort Send to Text

[Write to the Help Desk](#)
[NCBI](#) | [NLM](#) | [NIH](#)
[Department of Health & Human Services](#)
[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Aug 30 2004 06:52:01



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Book

Search PubMed for colostrum AND leukocyte AND colostrinin Go Clear

Limits Preview/Index History Clipboard Details

About Entrez

Display Summary Show: 500 Sort Send to Text

Text Version

Items 1-2 of 2

One page.

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

1: Kruzel ML, Janusz M, Lisowski J, Fischleigh RV, Georgiades JA. Related Articles, Links

Towards an understanding of biological role of colostrinin peptides.

J Mol Neurosci. 2001 Dec;17(3):379-89.

PMID: 11859934 [PubMed - indexed for MEDLINE]

2: Leszek J, Ingiot AD, Janusz M, Lisowski J, Krukowska K, Georgiades JA. Related Articles, Links

Colostrinin: a proline-rich polypeptide (PRP) complex isolated from ovine colostrum for treatment of Alzheimer's disease. A double-blind, placebo-controlled study.

Arch Immunol Ther Exp (Warsz). 1999;47(6):377-85.

PMID: 10608295 [PubMed - indexed for MEDLINE]


[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Aug 30 2004 06:52:01



Entrez PubMed Nucleotide Protein Genomes Structure OMIM PMC Journals Book

Search PubMed for PRP AND leukocyte AND colostrum Go Clear

Limits Preview/Index History Clipboard Details

About Entrez

Display Summary Show: 500 Sort Send to Text
Items 1-8 of 8 One page.

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

☐ 1: [Kruzel ML, Janusz M, Lisowski J, Fischleigh RV, Georgiades JA](#). Related Articles, Links

Towards an understanding of biological role of colostrinin peptides.
J Mol Neurosci. 2001 Dec;17(3):379-89.
PMID: 11859934 [PubMed - indexed for MEDLINE]

☐ 2: [Zablocka A, Janusz M, Rybka K, Wirkus-Romanowska I, Kupryszewski G, Lisowski J](#). Related Articles, Links

Cytokine-inducing activity of a proline-rich polypeptide complex (PRP) from ovine colostrum and its active nonapeptide fragment analogs.
Eur Cytokine Netw. 2001 Jul-Sep;12(3):462-7.
PMID: 11566627 [PubMed - indexed for MEDLINE]

☐ 3: [Leszek J, Inglot AD, Janusz M, Lisowski J, Krukowska K, Georgiades JA](#). Related Articles, Links

Colostrinin: a proline-rich polypeptide (PRP) complex isolated from ovine colostrum for treatment of Alzheimer's disease. A double-blind, placebo-controlled study.
Arch Immunol Ther Exp (Warsz). 1999;47(6):377-85.
PMID: 10608295 [PubMed - indexed for MEDLINE]

☐ 4: [Inglot AD, Janusz M, Lisowski J](#). Related Articles, Links

Colostrinine: a proline-rich polypeptide from ovine colostrum is a modest cytokine inducer in human leukocytes.
Arch Immunol Ther Exp (Warsz). 1996;44(4):215-24.
PMID: 9017161 [PubMed - indexed for MEDLINE]

☐ 5: [Janusz M](#). Related Articles, Links

[Proline-rich-polypeptide from ovine colostrum (PRP): its structure and properties. II]
Postepy Hig Med Dosw. 1988 May-Jun;42(3):237-59. Review. Polish. No abstract available.
PMID: 3073376 [PubMed - indexed for MEDLINE]

☐ 6: [Lisowski J, Wieczorek Z, Janusz M, Zimecki M](#). Related Articles, Links

Proline-rich polypeptide (PRP) from ovine colostrum. Bi-directional modulation of binding of peanut agglutinin, resistance to hydrocortisone, and helper activity in murine thymocytes.
Arch Immunol Ther Exp (Warsz). 1988;36(4):381-93.
PMID: 2977937 [PubMed - indexed for MEDLINE]

☐ 7: [Janusz M, Starosek K, Zimecki M, Wieczorek Z, Lisowski J](#). Related Articles, Links

A proline-rich polypeptide (PRP) with immunoregulatory properties isolated from ovine colostrum. Murine thymocytes have on their surface a receptor specific for PRP.
Arch Immunol Ther Exp (Warsz). 1986;34(4):427-36.
PMID: 3026278 [PubMed - indexed for MEDLINE]

☐ **8:** [Zimecki M, Janusz M, Staroscik K, Lisowski J, Wieczorek Z.](#)

[Related Articles, Links](#)



Effect of proline-rich polypeptide on donor cells in graft-versus-host reaction.

Immunology. 1982 Sep;47(1):141-7.

PMID: 6981586 [PubMed - indexed for MEDLINE]

Display	Summary	Show:	500	Sort	Send to	Text
---------	---------	-------	-----	------	---------	------


[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Aug 30 2004 06:52:01



Entrez PubMed Nucleotide Protein Genome Structure OMIM PMC Journals Books
Search PubMed for NP AND leukocyte AND colostrum Go Clear
Limits Preview/Index History Clipboard Details

About Entrez

Text Version

Entrez PubMed

Overview

Help | FAQ

Tutorial

New/Noteworthy

E-Utilities

PubMed Services

Journals Database

MeSH Database

Single Citation Matcher

Batch Citation Matcher

Clinical Queries

LinkOut

Cubby

Related Resources

Order Documents

NLM Gateway

TOXNET

Consumer Health

Clinical Alerts

ClinicalTrials.gov

PubMed Central

Display Summary Show: 500 Sort Send to Text
Items 1-2 of 2 One page.

☐ 1: [Zablocka A, Janusz M, Rybka K, Wirkus-Romanowska I, Kupryszewski G, Lisowski J.](#)

[Related Articles, Links](#)

Cytokine-inducing activity of a proline-rich polypeptide complex (PRP) from ovine colostrum and its active nonapeptide fragment analogs. Eur Cytokine Netw. 2001 Jul-Sep;12(3):462-7. PMID: 11566627 [PubMed - indexed for MEDLINE]

☐ 2: [Ingłot AD, Janusz M, Lisowski J.](#)

[Related Articles, Links](#)

Colostrinine: a proline-rich polypeptide from ovine colostrum is a modest cytokine inducer in human leukocytes. Arch Immunol Ther Exp (Warsz). 1996;44(4):215-24. PMID: 9017161 [PubMed - indexed for MEDLINE]

[Write to the Help Desk](#)

[NCBI](#) | [NLM](#) | [NIH](#)

[Department of Health & Human Services](#)

[Privacy Statement](#) | [Freedom of Information Act](#) | [Disclaimer](#)

Aug 30 2004 06:52:01

Connecting via Winsock to STN
Welcome to STN International! Enter x:x
***** Welcome to STN International *****
***** STN Columbus *****

FILE 'HOME' ENTERED AT 15:27:58 ON 08 SEP 2004

=> file BIOSCIENCE

FILE 'ADISCTI' ENTERED AT 15:28:07 ON 08 SEP 2004
COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISINSIGHT' ENTERED AT 15:28:07 ON 08 SEP 2004
COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 15:28:07 ON 08 SEP 2004
COPYRIGHT (C) 2004 Adis Data Information BV

FILE 'AGRICOLA' ENTERED AT 15:28:07 ON 08 SEP 2004

FILE 'AQUALINE' ENTERED AT 15:28:07 ON 08 SEP 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'ANABSTR' ENTERED AT 15:28:07 ON 08 SEP 2004
COPYRIGHT (c) 2004 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'ANTE' ENTERED AT 15:28:07 ON 08 SEP 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'AQUASCI' ENTERED AT 15:28:07 ON 08 SEP 2004
COPYRIGHT 2004 FAO (On behalf of the ASFA Advisory Board). All rights reserved.

FILE 'BIOBUSINESS' ENTERED AT 15:28:07 ON 08 SEP 2004
Copyright (c) 1998 The Thomson Corporation.

FILE 'BIOCOMMERCE' ENTERED AT 15:28:07 ON 08 SEP 2004
COPYRIGHT (C) 2004 BioCommerce Data Ltd. Richmond Surrey, United Kingdom. All rights reserved

FILE 'BIOENG' ENTERED AT 15:28:07 ON 08 SEP 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'BIOSIS' ENTERED AT 15:28:07 ON 08 SEP 2004
Copyright (c) 2004 The Thomson Corporation.

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 15:28:07 ON 08 SEP 2004
COPYRIGHT (C) 2004 THOMSON DERWENT AND INSTITUTE FOR SCIENTIFIC INFORMATION

FILE 'BIOTECHNO' ENTERED AT 15:28:07 ON 08 SEP 2004
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CABA' ENTERED AT 15:28:07 ON 08 SEP 2004
COPYRIGHT (C) 2004 CAB INTERNATIONAL (CABI)

FILE 'CANCERLIT' ENTERED AT 15:28:07 ON 08 SEP 2004

FILE 'CAPLUS' ENTERED AT 15:28:07 ON 08 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEABA-VTB' ENTERED AT 15:28:07 ON 08 SEP 2004
COPYRIGHT (c) 2004 DECHEMA eV

FILE 'CEN' ENTERED AT 15:28:07 ON 08 SEP 2004
COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CIN' ENTERED AT 15:28:07 ON 08 SEP 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

FILE 'CONFSCI' ENTERED AT 15:28:07 ON 08 SEP 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'CROPB' ENTERED AT 15:28:07 ON 08 SEP 2004

COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'CROPU' ENTERED AT 15:28:07 ON 08 SEP 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DISSABS' ENTERED AT 15:28:07 ON 08 SEP 2004
COPYRIGHT (C) 2004 Proquest Information and Learning Company; All Rights Reserved.

FILE 'DDFB' ACCESS NOT AUTHORIZED

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 15:28:07 ON 08 SEP 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DRUGB' ENTERED AT 15:28:07 ON 08 SEP 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'DRUGMONOG2' ENTERED AT 15:28:07 ON 08 SEP 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'IMSDRUGNEWS' ENTERED AT 15:28:07 ON 08 SEP 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 15:28:07 ON 08 SEP 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'IMSRESEARCH' ENTERED AT 15:28:07 ON 08 SEP 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'EMBAL' ENTERED AT 15:28:07 ON 08 SEP 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'EMBASE' ENTERED AT 15:28:07 ON 08 SEP 2004
COPYRIGHT (C) 2004 Elsevier Inc. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 15:28:07 ON 08 SEP 2004
COPYRIGHT (C) 2004 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'FEDRIP' ENTERED AT 15:28:07 ON 08 SEP 2004

FILE 'FOMAD' ENTERED AT 15:28:07 ON 08 SEP 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FOREGE' ENTERED AT 15:28:07 ON 08 SEP 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FROSTI' ENTERED AT 15:28:07 ON 08 SEP 2004
COPYRIGHT (C) 2004 Leatherhead Food Research Association

FILE 'FSTA' ENTERED AT 15:28:07 ON 08 SEP 2004
COPYRIGHT (C) 2004 International Food Information Service

FILE 'GENBANK' ENTERED AT 15:28:07 ON 08 SEP 2004

FILE 'HEALSAFE' ENTERED AT 15:28:07 ON 08 SEP 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 15:28:07 ON 08 SEP 2004
COPYRIGHT (C) 2004 IFI CLAIMS(R) Patent Services (IFI)

FILE 'IMSPRODUCT' ENTERED AT 15:28:07 ON 08 SEP 2004
COPYRIGHT (C) 2004 IMSWORLD Publications Ltd

FILE 'JICST-EPLUS' ENTERED AT 15:28:07 ON 08 SEP 2004
COPYRIGHT (C) 2004 Japan Science and Technology Agency (JST)

FILE 'KOSMET' ENTERED AT 15:28:07 ON 08 SEP 2004
COPYRIGHT (C) 2004 International Federation of the Societies of Cosmetics Chemists

FILE 'LIFESCI' ENTERED AT 15:28:07 ON 08 SEP 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'MEDICONF' ENTERED AT 15:28:07 ON 08 SEP 2004
COPYRIGHT (c) 2004 FAIRBASE Datenbank GmbH, Hannover, Germany

FILE 'MEDLINE' ENTERED AT 15:28:07 ON 08 SEP 2004

FILE 'NIOSHTIC' ENTERED AT 15:28:07 ON 08 SEP 2004
COPYRIGHT (C) 2004 U.S. Secretary of Commerce on Behalf of the U.S. Government

FILE 'NTIS' ENTERED AT 15:28:07 ON 08 SEP 2004
Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.
All rights reserved. (2004)

FILE 'NUTRACEUT' ENTERED AT 15:28:07 ON 08 SEP 2004
Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'OCEAN' ENTERED AT 15:28:07 ON 08 SEP 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'PASCAL' ENTERED AT 15:28:07 ON 08 SEP 2004
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2004 INIST-CNRS. All rights reserved.

FILE 'PCTGEN' ENTERED AT 15:28:07 ON 08 SEP 2004
COPYRIGHT (C) 2004 WIPO

FILE 'PHAR' ENTERED AT 15:28:07 ON 08 SEP 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHARMAML' ENTERED AT 15:28:07 ON 08 SEP 2004
Copyright 2004 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PHIC' ENTERED AT 15:28:07 ON 08 SEP 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PHIN' ENTERED AT 15:28:07 ON 08 SEP 2004
COPYRIGHT (C) 2004 PJB Publications Ltd. (PJB)

FILE 'PROMT' ENTERED AT 15:28:07 ON 08 SEP 2004
COPYRIGHT (C) 2004 Gale Group. All rights reserved.

FILE 'PROUSDDR' ENTERED AT 15:28:07 ON 08 SEP 2004
COPYRIGHT (C) 2004 Prous Science

FILE 'RDISCLOSURE' ENTERED AT 15:28:07 ON 08 SEP 2004
COPYRIGHT (C) 2004 Kenneth Mason Publications Ltd.

FILE 'SCISEARCH' ENTERED AT 15:28:07 ON 08 SEP 2004
Copyright (c) 2004 The Thomson Corporation.

FILE 'SYNTHLINE' ENTERED AT 15:28:07 ON 08 SEP 2004
COPYRIGHT (C) 2004 Prous Science

FILE 'TOXCENTER' ENTERED AT 15:28:07 ON 08 SEP 2004
COPYRIGHT (C) 2004 ACS

FILE 'USPATFULL' ENTERED AT 15:28:07 ON 08 SEP 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 15:28:07 ON 08 SEP 2004
CA INDEXING COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'VETB' ENTERED AT 15:28:07 ON 08 SEP 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'VETU' ENTERED AT 15:28:07 ON 08 SEP 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WATER' ENTERED AT 15:28:07 ON 08 SEP 2004
COPYRIGHT (C) 2004 Cambridge Scientific Abstracts (CSA)

FILE 'WPIDS' ENTERED AT 15:28:07 ON 08 SEP 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WPIFV' ENTERED AT 15:28:07 ON 08 SEP 2004
COPYRIGHT (C) 2004 THOMSON DERWENT

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

=> s colostrum

50 FILES SEARCHED...

L1 45003 COLOSTRUM

=> s colostrinin OR PRP OR NP

36 FILES SEARCHED...

L2 246830 COLOSTRININ OR PRP OR NP

=> s cytokine OR leukocyte

33 FILES SEARCHED...

L3 2383993 CYTOKINE OR LEUKOCYTE

=> s L1 AND L2 AND L3

52 FILES SEARCHED...

L4 179 L1 AND L2 AND L3

=> DUP REM L4

DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, BIOCOMMERCE, DGENE, DRUGMONOG2, IMSRESEARCH, FEDRIP, FOREGE, GENBANK, IMSPRODUCT, KOSMET, MEDICONF, NUTRACEUT, PCTGEN, PHAR, PHARMAML, PROUSDDR, RDISCLOSURE, SYNTHLINE'. ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE

PROCESSING COMPLETED FOR L4

L5 134 DUP REM L4 (45 DUPLICATES REMOVED)

=> D L5 1-134

L5 ANSWER 1 OF 134 USPATFULL on STN

AN 2004:221782 USPATFULL

TI Peptides fragments of ***colostrinin*** and their use
IN Georgiades, Jerzy A., Houston, TX, UNITED STATES

PI US 2004171553 A1 20040902

AI US 2003-182110 A1 20030421 (10)

WO 2001-GB329 20010126

PRAI GB 2000-1825 20000126

DT Utility

FS APPLICATION

LN.CNT 575

INCL INCLM: 514/014.000

INCLS: 530/327.000

NCL NCLM: 514/014.000

NCLS: 530/327.000

IC [7]

ICM: A61K038-10

ICS: C07K007-08

L5 ANSWER 2 OF 134 USPATFULL on STN

AN 2004:133369 USPATFULL

TI Product

IN Brekke, Ole Henrik Andre, Oslo, NORWAY

Lauvrak, Vigdis, Oslo, NORWAY

Sandie, Inger, Oslo, NORWAY

PI US 2004101905 A1 20040527

AI US 2003-433452 A1 20031003 (10)

WO 2001-GB5301 20011130

PRAI GB 2000-29407 20001201

DT Utility

FS APPLICATION

LN.CNT 2076

INCL INCLM: 435/007.100

INCLS: 530/388.220

NCL NCLM: 435/007.100

NCLS: 530/388.220

IC [7]

ICM: G01N033-53

ICS: C07K016-28

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 3 OF 134 USPATFULL on STN

AN 2004:89782 USPATFULL

TI Transgenic ungulates capable of human antibody production

IN Robl, James M., Brandon, SD, UNITED STATES

Collas, Philippe, Oslo, NORWAY

Sullivan, Eddie, Manhattan, KS, UNITED STATES

Kasinathan, P., Manhattan, KS, UNITED STATES

Goldsby, Richard A., Leverett, MA, UNITED STATES
Kuroiwa, Yoshimi, Sionx Falls, JAPAN
Tomizuka, Kazuma, Takasaki, JAPAN
Ishida, Isao, Isehara, JAPAN
PI US 2004068760 A1 20040408
AI US 2003-441503 A1 20030519 (10)
RLI Continuation-in-part of Ser. No. US 2001-988115, filed on 16 Nov 2001,
PENDING Continuation-in-part of Ser. No. US 2000-714185, filed on 17 Nov
2000, PENDING Continuation-in-part of Ser. No. US 2001-32191, filed on
21 Dec 2001, PENDING
PRAI US 2002-381531P 20020517 (60)
US 2002-425056P 20021108 (60)
US 2001-311625P 20010809 (60)
US 2000-256458P 20001220 (60)
US 1999-166410P 19991119 (60)
US 2000-258151P 20001222 (60)
DT Utility
FS APPLICATION
LN.CNT 8417
INCL INCLM: 800/006.000
INCLS: 800/014.000; 800/015.000; 800/016.000; 800/017.000
NCL NCLM: 800/006.000
NCLS: 800/014.000; 800/015.000; 800/016.000; 800/017.000
IC [7]
ICM: A01K067-027
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 4 OF 134 USPATFULL on STN
AN 2004:50421 USPATFULL
TI Recombinant vaccine against West Nile Virus
IN Audonnet, Jean-Christophe Francis, Lyon, FRANCE
Minke, Jules Maarten, Corbas, FRANCE
Loosmore, Sheena May, Aurora, CANADA
Karaca, Kemal, Athens, GA, UNITED STATES
PI US 2004037848 A1 20040226
AI US 2003-374953 A1 20030226 (10)
RLI Continuation-in-part of Ser. No. US 2002-116298, filed on 4 Apr 2002,
PENDING
PRAI US 2001-281923P 20010406 (60)
DT Utility
FS APPLICATION
LN.CNT 3176
INCL INCLM: 424/199.100
INCLS: 514/044.000
NCL NCLM: 424/199.100
NCLS: 514/044.000
IC [7]
ICM: A61K039-12
ICS: A61K048-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 5 OF 134 USPATFULL on STN
AN 2004:18793 USPATFULL
TI Targets, methods, and reagents for diagnosis and treatment of
schizophrenia
IN Gerber, David J., Somerville, MA, UNITED STATES
Karayiorgou, Maria, New York, NY, UNITED STATES
Miyakawa, Tsuyoshi, Kamigyo-Ku Kyoto, JAPAN
Tonegawa, Susumu, Chestnut Hill, MA, UNITED STATES
PI US 2004014095 A1 20040122
AI US 2003-400348 A1 20030326 (10)
PRAI US 2002-367944P 20020326 (60)
US 2003-452813P 20030307 (60)
DT Utility
FS APPLICATION
LN.CNT 5713
INCL INCLM: 435/006.000
NCL NCLM: 435/006.000
IC [7]
ICM: C12Q001-68
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 6 OF 134 USPATFULL on STN
AN 2004:9489 USPATFULL
TI Bovine lactation associated immunotropic protein (CD14), encoding gene
and application in B cell activation

IN Julius, Michael H., Toronto, CANADA
Filipp, Dominik, Woodbridge, CANADA
Alizadeh-Khiavi, Kamel, London, CANADA
PA The Arthritis & Autoimmunity Research Centre Foundation, Toronto, CANADA
(non-U.S. corporation)
PI US 6676985 B1 20040113
AI US 1999-313177 19990518 (9)
RLI Continuation of Ser. No. WO 1997-CA880, filed on 18 Nov 1997
Continuation-in-part of Ser. No. US 1996-746883, filed on 18 Nov 1996,
now patented, Pat. No. US 6093693
DT Utility
FS GRANTED
LN.CNT 1787
INCL INCLM: 426/645.000
INCLS: 426/657.000; 426/801.000; 514/008.000; 514/021.000; 530/351.000
NCL NCLM: 426/645.000
NCLS: 426/657.000; 426/801.000; 514/008.000; 514/021.000; 530/351.000
IC [7]
ICM: A23L001-31
ICS: A23J001-02; A61K038-16; A61K038-00; C07K001-00
EXF 514/8; 514/21; 530/351; 426/645; 426/657; 426/801
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 7 OF 134 USPATFULL on STN
AN 2004:4504 USPATFULL
TI Tumor necrosis factor receptor 2
IN Stanton, Jr., Vincent P., Belmont, MA, United States
PA Nuvelo, Inc., Sunnyvale, CA, United States (U.S. corporation)
PI US 6673908 B1 20040106
AI US 2001-968455 20011001 (9)
RLI Division of Ser. No. US 2000-649035, filed on 25 Aug 2000
Continuation-in-part of Ser. No. US 2000-590749, filed on 8 Jun 2000,
now abandoned Continuation-in-part of Ser. No. US 2000-495780, filed on
1 Feb 2000, now abandoned Continuation-in-part of Ser. No. US
2000-492712, filed on 27 Jan 2000, now abandoned Continuation-in-part of
Ser. No. WO 2000-US1392, filed on 20 Jan 2000 Continuation-in-part of
Ser. No. US 968455 Continuation-in-part of Ser. No. US 1999-451252,
filed on 29 Nov 1999, now abandoned Continuation-in-part of Ser. No. US
1999-427835, filed on 26 Oct 1999, now abandoned Continuation-in-part of
Ser. No. US 1999-414330, filed on 6 Oct 1999, now abandoned
Continuation-in-part of Ser. No. US 1999-389993, filed on 3 Sep 1999,
now abandoned Continuation-in-part of Ser. No. US 1999-370841, filed on
9 Aug 1999, now abandoned Continuation-in-part of Ser. No. US
1999-300747, filed on 26 Apr 1999, now abandoned
PRAI US 1999-131334P 19990426 (60)
US 1999-131191P 19990426 (60)
US 1999-121047P 19990222 (60)
DT Utility
FS GRANTED
LN.CNT 17463
INCL INCLM: 536/022.100
INCLS: 536/023.100; 536/024.300; 536/024.310; 536/024.330; 435/006.000;
435/091.100; 435/091.200
NCL NCLM: 536/022.100
NCLS: 435/006.000; 435/091.100; 435/091.200; 536/023.100; 536/024.300;
536/024.310; 536/024.330
IC [7]
ICM: C07H021-04
ICS: C12Q001-68; C12P019-34
EXF 435/6; 435/91.1; 435/91.2; 536/22.1; 536/23.1; 536/24.3; 536/24.31;
536/24.33
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 8 OF 134 USPATFULL on STN
AN 2003:270720 USPATFULL
TI Immunostimulating properties of a fragment of tgf-beta
IN Kaastrup, Peter, Maaloev, DENMARK
PI US 2003190322 A1 20031009
AI US 2003-240421 A1 20030407 (10)
WO 2001-DK218 20010330
PRAI DK 2000-540 20000331
DT Utility
FS APPLICATION
LN.CNT 2624
INCL INCLM: 424/185.100
INCLS: 530/324.000

NCL NCLM: 424/185.100
NCLS: 530/324.000
IC [7]
ICM: A61K039-00
ICS: C07K014-495
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 9 OF 134 USPATFULL on STN
AN 2003:270709 USPATFULL
TI Molecules with extended half-lives, compositions and uses thereof
IN Dall'Acqua, William, Gaithersburg, MD, UNITED STATES
Johnson, Leslie S., Germantown, MD, UNITED STATES
Ward, Elizabeth Sally, Dallas, TX, UNITED STATES
PI US 2003190311 A1 20031009
AI US 2001-20354 A1 20011212 (10)
PRAI US 2000-254884P 20001212 (60)
US 2001-289760P 20010509 (60)
DT Utility
FS APPLICATION
LN.CNT 5309
INCL INCLM: 424/130.100
INCLS: 530/387.300
NCL NCLM: 424/130.100
NCLS: 530/387.300
IC [7]
ICM: A61K039-395
ICS: C07K016-44
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 10 OF 134 USPATFULL on STN
AN 2003:152330 USPATFULL
TI Cell-based vaccine
IN Eibl, Martha, Vienna, AUSTRIA
Kreil, Thomas, Klosterneuburg, AUSTRIA
Mannhalter, Josef, Vienna, AUSTRIA
Eibl, Johann, Vienna, AUSTRIA
Kerschbaum, Astrid, Vienna, AUSTRIA
Bruhl, Peter, Vienna, AUSTRIA
PI US 2003103996 A1 20030605
AI US 2002-255423 A1 20020926 (10)
RLI Continuation of Ser. No. US 1998-224807, filed on 31 Dec 1998, ABANDONED
Continuation of Ser. No. WO 1997-EP3452, filed on 2 Jul 1997, UNKNOWN
PRAI DE 1996-19626614 19960702
DT Utility
FS APPLICATION
LN.CNT 980
INCL INCLM: 424/185.100
INCLS: 424/204.100; 424/192.100; 424/186.100; 435/006.000
NCL NCLM: 424/185.100
NCLS: 424/204.100; 424/192.100; 424/186.100; 435/006.000
IC [7]
ICM: A61K039-12
ICS: A61K039-00; C12Q001-68
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 11 OF 134 USPATFULL on STN
AN 2003:133521 USPATFULL
TI Use of ***colostrinin***, constituent peptides thereof, and analogs
thereof, as oxidative stress regulators
IN Stanton, G. John, Texas City, TX, UNITED STATES
Hughes, Thomas K., JR., Galveston, TX, UNITED STATES
Boldogh, Istvan, Galveston, TX, UNITED STATES
PA Board of Regents, The University of Texas System, Austin, TX (U.S.
corporation)
PI US 2003091606 A1 20030515
AI US 2002-281652 A1 20021028 (10)
RLI Division of Ser. No. US 2000-641803, filed on 17 Aug 2000, GRANTED, Pat.
No. US 6500798
PRAI US 1999-149310P 19990817 (60)
DT Utility
FS APPLICATION
LN.CNT 1266
INCL INCLM: 424/401.000
INCLS: 514/014.000; 514/013.000; 514/015.000; 530/300.000; 530/325.000;
530/326.000; 530/327.000; 530/328.000; 530/329.000
NCL NCLM: 424/401.000

NCLS: 514/014.000; 514/013.000; 514/015.000; 530/300.000; 530/325.000;
530/326.000; 530/327.000; 530/328.000; 530/329.000

IC [7]
ICM: A61K038-00
ICS: A61K006-00; A61K007-00; C07K016-00; C07K014-00; C07K007-00;
C07K005-00; C07K004-00; C07K002-00; A61K038-04; C07K017-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 12 OF 134 USPATFULL on STN
AN 2003:119705 USPATFULL
TI Fusion molecules and treatment of IgE-mediated allergic diseases
IN Saxon, Andrew, Santa Monica, CA, UNITED STATES
Zhang, Ke, Los Angeles, CA, UNITED STATES
Zhu, Daocheng, Los Angeles, CA, UNITED STATES
PI US 2003082190 A1 20030501
AI US 2001-847208 A1 20010501 (9)
DT Utility
FS APPLICATION
LN.CNT 7500
INCL INCLM: 424/178.100
INCLS: 530/391.100; 435/069.700; 435/320.100; 435/334.000; 536/023.530
NCL NCLM: 424/178.100
NCLS: 530/391.100; 435/069.700; 435/320.100; 435/334.000; 536/023.530
IC [7]
ICM: A61K039-395
ICS: C07H021-04; C12P021-02; C12N005-06; C07K016-28
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 13 OF 134 USPATFULL on STN
AN 2003:92706 USPATFULL
TI Fusion molecules and methods for treatment of immune diseases
IN Saxon, Andrew, Santa Monica, CA, UNITED STATES
PI US 2003064063 A1 20030403
AI US 2001-439 A1 20011024 (10)
RLI Continuation-in-part of Ser. No. US 2001-847208, filed on 1 May 2001,
PENDING
DT Utility
FS APPLICATION
LN.CNT 4242
INCL INCLM: 424/131.100
INCLS: 530/387.200; 435/069.700; 435/327.000; 435/320.100; 536/023.530
NCL NCLM: 424/131.100
NCLS: 530/387.200; 435/069.700; 435/327.000; 435/320.100; 536/023.530
IC [7]
ICM: A61K039-395
ICS: C07H021-04; C12P021-02; C12N005-06; C07K016-42
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 14 OF 134 USPATFULL on STN
AN 2003:86158 USPATFULL
TI Immunoglobulin class switch recombination
IN Saxon, Andrew, Santa Monica, CA, UNITED STATES
Zhang, Ke, Los Angeles, CA, UNITED STATES
PI US 2003059763 A1 20030327
AI US 2001-770169 A1 20010126 (9)
DT Utility
FS APPLICATION
LN.CNT 2036
INCL INCLM: 435/004.000
NCL NCLM: 435/004.000
IC [7]
ICM: C12Q001-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 15 OF 134 USPATFULL on STN
AN 2003:161878 USPATFULL
TI Polymyxin B conjugates
IN Shekhani, Mohammed Saleh, Madison, WI, United States
Schatz, Robert W., New Glarus, WI, United States
Pugh, Charles, Middleton, WI, United States
Panasik, Jr., Nicholas, Madison, WI, United States
Stafford, Douglas, Madison, WI, United States
PA Promega Corporation, Madison, WI, United States (U.S. corporation)
PI US 6579696 B1 20030617
AI US 1995-482191 19950607 (8)
RLI Continuation-in-part of Ser. No. US 1993-169701, filed on 17 Dec 1993,

now patented, Pat. No. US 5545721 Continuation-in-part of Ser. No. US 1992-995388, filed on 21 Dec 1992, now abandoned
 DT Utility
 FS GRANTED
 LN.CNT 6203
 INCL INCLM: 435/068.100
 INCLS: 514/002.000; 530/300.000; 530/333.000; 530/350.000; 530/391.700
 NCL NCLM: 435/068.100
 NCLS: 514/002.000; 530/300.000; 530/333.000; 530/350.000; 530/391.700
 IC [7]
 ICM: C12P021-06
 ICS: A01N037-18; A61K038-00; C07K014-00
 EXF 514/2; 530/391.7; 530/300; 530/333; 530/350; 435/68.1
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 16 OF 134 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 1
 AN 2004:76870 BIOSIS
 DN PREV200400078893
 TI A proline-rich polypeptide complex (***PRP***) from ovine ***colostrum***. Studies on the effect of ***PRP*** on nitric oxide (NO) production induced by LPS in THP-1 cells.
 AU Mikulska, Joanna Elzbieta [Reprint Author]; Lisowski, Jozef
 CS Department of Immunochemistry, Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, 12 R. Weigla, 53-114, Wroclaw, Poland mikulska@immuno.iitd.pan.wroc.pl
 SO Immunopharmacology and Immunotoxicology, (November 2003) Vol. 25, No. 4, pp. 645-654. print.
 CODEN: IITOEf. ISSN: 0892-3973.
 DT Article
 LA English
 ED Entered STN: 4 Feb 2004
 Last Updated on STN: 4 Feb 2004

L5 ANSWER 17 OF 134 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on STN DUPLICATE 2
 AN 2003:404201 BIOSIS
 DN PREV200300404201
 TI Modulation of 4HNE-mediated signaling by proline-rich peptides from ovine ***colostrum***.
 AU Boldogh, Istvan; Liebenthal, Daniel; Hughes, T. Kley; Juelich, Terry L.; Georgiades, Jerzy A.; Kruzel, Marian L.; Stanton, G. John [Reprint Author]
 CS Department of Microbiology and Immunology, The University of Texas Medical Branch, Galveston, TX, 77555, USA jstanton@utmb.edu
 SO Journal of Molecular Neuroscience, (April 2003) Vol. 20, No. 2, pp. 125-134. print.
 ISSN: 0895-8696 (ISSN online).
 DT Article
 LA English
 ED Entered STN: 3 Sep 2003
 Last Updated on STN: 3 Sep 2003

L5 ANSWER 18 OF 134 ADISCTI COPYRIGHT (C) 2004 Adis Data Information BV on STN
 AN 2003:6869 ADISCTI
 DN 809026793
 TI ColostrininTM clinical study to be published in Journal of Alzheimer's Disease.
 ADIS TITLE: ***Colostrinin*** : therapeutic use.
 Alzheimer's disease.
 AU ReGen Therapeutics Plc.
 CS ReGen Therapeutics.
 SO Media Release (Oct 8, 2003)
 DT Study
 RE Alzheimer's Disease and Cognition Disorders| Neurological Disorders
 FS summary
 LA English
 WC 258

L5 ANSWER 19 OF 134 USPATFULL on STN DUPLICATE 3
 AN 2002:329521 USPATFULL
 TI Dietary supplement comprising lactoferrin and citrus pectin
 IN Gohlke, Marcus B., Houston, TX, UNITED STATES
 Cockrum, Richard H., Perry, IA, UNITED STATES
 PA Lactoferrin Products Company (U.S. corporation)

PI US 2002187200 A1 20021212
US 6780438 B2 20040824
AI US 2002-209546 A1 20020731 (10)
RLI Division of Ser. No. US 2001-945997, filed on 4 Sep 2001, PENDING
Division of Ser. No. US 2001-778294, filed on 6 Feb 2001, GRANTED, Pat.
No. US 6410058 Division of Ser. No. US 1999-370654, filed on 6 Aug 1999,
GRANTED, Pat. No. US 6258383
PRAI US 1998-96697P 19980814 (60)
DT Utility
FS APPLICATION
LN.CNT 871
INCL INCLM: 424/535.000
INCLS: 424/736.000
NCL NCLM: 424/535.000
NCLS: 424/440.000; 424/441.000; 424/464.000; 424/736.000
IC [7]
ICM: A61K035-20
ICS: A61K035-78

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 20 OF 134 USPATFULL on STN DUPLICATE 4
AN 2002:8076 USPATFULL
TI Dietary supplement combining ***colostrum*** and lactoferrin in a
mucosal delivery format
IN Gohlke, Marcus B., Houston, TX, UNITED STATES
Cockrum, Richard H., Perry, IA, UNITED STATES
PI US 2002004073 A1 20020110
US 6475511 B2 20021105
AI US 2001-945997 A1 20010904 (9)
RLI Division of Ser. No. US 2001-778294, filed on 6 Feb 2001, PENDING
Division of Ser. No. US 1999-370654, filed on 6 Aug 1999, GRANTED, Pat.
No. US 6258383
PRAI US 1998-96697P 19980814 (60)
DT Utility
FS APPLICATION
LN.CNT 871
INCL INCLM: 424/535.000
INCLS: 514/002.000
NCL NCLM: 424/441.000
NCLS: 424/440.000; 424/464.000; 424/535.000; 424/736.000
IC [7]
ICM: A61K035-20
ICS: A61K038-40

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 21 OF 134 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2002:142539 CAPLUS
DN 136:194245
TI Use of ***colostrinin***, constituent peptides thereof, and analogs
thereof for inducing ***cytokines***
IN Stanton, G. John; Hughes, Thomas K., Jr.; Boldogh, Istvan; Georgiades,
Jerzy
PA The University of Texas System, USA; Regen Therapeutics PLC
SO PCT Int. Appl., 54 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002013849	A1	20020221	WO 2000-US22775	20000817
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
	AU 2000067883	A5	20020225	AU 2000-67883	20000817
PRAI	WO 2000-US22775	A	20000817		
RE.CNT	4	THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT			

L5 ANSWER 22 OF 134 USPATFULL on STN

AN 2002:287153 USPATFULL
TI Vaccine chip technology exploiting immunostimulating fragment of
TGF-BETA
IN Kaastrup, Peter, Maafoev, DENMARK
PI US 2002160012 A1 20021031
AI US 2001-822873 A1 20010402 (9)
PRAI DK 2000-540 20000331
US 2000-246973P 20001113 (60)
DT Utility
FS APPLICATION
LN.CNT 2659
INCL INCLM: 424/185.100
NCL NCLM: 424/185.100
IC [7]
ICM: A61K039-00
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 23 OF 134 USPATFULL on STN
AN 2002:265555 USPATFULL
TI DNA encoding bovine immunoglobulin a inducing protein and uses therefor
IN Estes, D. Mark, Rocheport, MO, UNITED STATES
Austin, Amy, Phoenix, AZ, UNITED STATES
Haas, Karen, Chapel Hill, NC, UNITED STATES
PI US 2002146427 A1 20021010
AI US 2001-999256 A1 20011031 (9)
PRAI US 2000-244467P 20001031 (60)
DT Utility
FS APPLICATION
LN.CNT 2086
INCL INCLM: 424/185.100
INCLS: 435/183.000; 435/069.300; 435/325.000; 435/326.000; 435/320.100;
536/023.200
NCL NCLM: 424/185.100
NCLS: 435/183.000; 435/069.300; 435/325.000; 435/326.000; 435/320.100;
536/023.200
IC [7]
ICM: A61K039-00
ICS: C12N005-06; C07H021-04; C12N009-00; C12P021-02; C12N015-09;
C12N015-63; C12N015-74; C12N005-02; C12N015-00; C12N015-70; C12N005-00;
C12N005-16
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 24 OF 134 USPATFULL on STN
AN 2002:221786 USPATFULL
TI Dietary supplement compositions
IN McAnalley, Bill H., Grand Prairie, TX, UNITED STATES
PI US 2002119928 A1 20020829
AI US 2001-1439 A1 20011025 (10)
PRAI US 2000-244029P 20001027 (60)
DT Utility
FS APPLICATION
LN.CNT 1266
INCL INCLM: 514/012.000
INCLS: 514/054.000; 424/535.000
NCL NCLM: 514/012.000
NCLS: 514/054.000; 424/535.000
IC [7]
ICM: A61K038-40
ICS: A61K031-732; A61K031-716
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 25 OF 134 USPATFULL on STN
AN 2002:214240 USPATFULL
TI 47169 and 33935, novel human glycosyl transferases and uses thereof
IN Meyers, Rachel E., Newton, MA, UNITED STATES
Williamson, Mark, Saugus, MA, UNITED STATES
PA Millennium Pharmaceuticals, Inc., Cambridge, MA, UNITED STATES, 02139
(2)
PI US 2002115628 A1 20020822
AI US 2001-1851 A1 20011120 (10)
PRAI US 2000-249939P 20001120 (60)
DT Utility
FS APPLICATION
LN.CNT 5365
INCL INCLM: 514/044.000
INCLS: 536/023.200

NCL NCLM: 514/044.000
NCLS: 536/023.200
IC [7]
ICM: A61K048-00
ICS: C07H021-04
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 26 OF 134 USPATFULL on STN
AN 2002:12251 USPATFULL
TI Compositions and methods for the diagnosis, treatment and prevention of
steroid hormone responsive cancers
IN Sirbasku, David A., Houston, TX, UNITED STATES
PI US 2002006630 A1 20020117
AI US 2001-852547 A1 20010510 (9)
PRAI US 2000-203314P 20000510 (60)
DT Utility
FS APPLICATION
LN.CNT 10394
INCL INCLM: 435/007.230
INCLS: 424/085.100; 424/155.100
NCL NCLM: 435/007.230
NCLS: 424/085.100; 424/155.100
IC [7]
ICM: G01N033-574
ICS: A61K039-395
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 27 OF 134 USPATFULL on STN
AN 2002:346890 USPATFULL
TI Use of ***colostrinin***, constituent peptides thereof, and analogs
thereof, as oxidative stress regulators
IN Stanton, G. John, Texas City, TX, United States
Hughes, Jr., Thomas K., Galveston, TX, United States
Boldogh, Istvan, Galveston, TX, United States
PA Board of Regents, The University of Texas System, Austin, TX, United
States (U.S. corporation)
PI US 6500798 B1 20021231
AI US 2000-641803 20000817 (9)
PRAI US 1999-149310P 19990817 (60)
DT Utility
FS GRANTED
LN.CNT 1305
INCL INCLM: 514/002.000
INCLS: 514/002.000; 514/012.000; 514/013.000; 514/014.000; 514/015.000;
514/016.000; 514/017.000; 514/018.000; 530/300.000; 530/324.000;
530/326.000; 530/327.000; 530/328.000; 530/329.000; 530/334.000;
530/350.000; 424/535.000
NCL NCLM: 514/002.000
NCLS: 424/535.000; 514/012.000; 514/013.000; 514/014.000; 514/015.000;
514/016.000; 514/017.000; 514/018.000; 530/300.000; 530/324.000;
530/326.000; 530/327.000; 530/328.000; 530/329.000; 530/334.000;
530/350.000
IC [7]
ICM: C07K014-47
ICS: C07K001-14; C07K007-06; A61K035-20; A61K038-08
EXF 424/535; 514/12; 514/2; 514/13; 514/14; 514/15; 514/16; 514/17; 514/18;
530/350; 530/324; 530/326; 530/327; 530/328; 530/329; 530/334; 530/300
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 28 OF 134 EMBASE COPYRIGHT 2004 ELSEVIER INC. ALL RIGHTS
RESERVED. on STN
AN 2002393937 EMBASE
TI ***Colostrinin***.RTM. proline-rich polypeptide complex from ovine
colostrum - A long-term study of its efficacy in Alzheimer's
disease.
AU Leszek J.; Inglot A.D.; Janusz M.; Byczkiewicz F.; Kiejna A.; Georgiades
J.; Lisowski J.
CS Dr. J. Leszek, Department of Psychiatry, Medical University, ul.
Kraszewskiego 25, 50-229 Wrocław, Poland. jleszek@psych.am.wroc.pl
SO Medical Science Monitor, (1 Oct 2002) 8/10 (PI93-PI96).
Refs: 26
ISSN: 1234-1010 CODEN: MSMOFR
CY Poland
DT Journal; Article
FS 008 Neurology and Neurosurgery
020 Gerontology and Geriatrics

037 Drug Literature Index
 038 Adverse Reactions Titles
 LA English
 SL English

L5 ANSWER 29 OF 134 USPATFULL on STN DUPLICATE 5
 AN 2001:119060 USPATFULL
 TI Methods of use for dietary compositions comprising lactoferrin and
 colostrum
 IN Gohlke, Marcus B., Houston, TX, United States
 Cockrum, Richard H., Perry, IA, United States
 PA Lactoferrin Products Company. (U.S. corporation)
 PI US 2001009681 A1 20010726
 US 6410058 B2 20020625
 AI US 2001-778294 A1 20010206 (9)
 RLI Division of Ser. No. US 1999-370654, filed on 6 Aug 1999, PENDING
 PRAI US 1998-96697P 19980814 (60)
 DT Utility
 FS APPLICATION
 LN.CNT 871
 INCL INCLM: 424/535.000
 NCL NCLM: 424/535.000
 NCLS: 424/440.000; 424/441.000; 424/464.000; 424/736.000
 IC [7]
 ICM: A61K035-20
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 30 OF 134 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2001:136927 CAPLUS
 DN 134:188199
 TI Use of ***colostrinin***, constituent peptides, and analogs for
 inducing ***cytokines*** and as blood cell regulators
 IN Stanton, G. John; Hughes, Thomas K., Jr.; Boldogh, Istvan; Georgiades,
 Jerzy
 PA The University of Texas System, USA; Regen Therapeutics PLC
 SO PCT Int. Appl., 51 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001011937	A2	20010222	WO 2000-US22818	20000817
WO 2001011937	A3	20010907		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IS, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG			
AU 2000069197	A5	20010313	AU 2000-69197	20000817
EP 1224217	A2	20020724	EP 2000-957601	20000817
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL			
PRAI US 1999-149311P	P	19990817		
WO 2000-US22818	W	20000817		

L5 ANSWER 31 OF 134 USPATFULL on STN
 AN 2001:107469 USPATFULL
 TI Dietary supplement combining ***colostrum*** and lactoferrin in a
 mucosal delivery format
 IN Gohlke, Marcus B., Houston, TX, United States
 Cockrum, Richard H., Perry, IA, United States
 PA Lactoferrin Products Company, Houston, TX, United States (U.S.
 corporation)
 PI US 6258383 B1 20010710
 AI US 1999-370654 19990806 (9)
 DT Utility
 FS GRANTED
 LN.CNT 795
 INCL INCLM: 424/535.000
 INCLS: 454/195.100; 454/440.000; 454/441.000
 NCL NCLM: 424/535.000

IC NCLS: 424/048.000; 424/440.000; 424/441.000; 424/736.000; 514/054.000
[7]
ICM: A61K035-20
ICS: A61K035-78; A61K009-20
EXF 424/535; 424/195.1; 424/441; 424/440
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 32 OF 134 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
STN DUPLICATE 6
AN 2002:373856 BIOSIS
DN PREV200200373856
TI ***Cytokine*** -inducing activity of a proline-rich polypeptide complex
(***PRP***) from ovine ***colostrum*** and its active nonapeptide
fragment analogs.
AU Zablocka, Agnieszka; Janusz, Maria; Rybka, Katarzyna; Wirkus-Romanowska,
Irena; Kupryszewski, Gotfryd; Lisowski, Jozef [Reprint author]
CS Department of Immunochemistry, Institute of Immunology and Experimental
Therapy, Polish Academy of Sciences, 12 R. Weigla, 53 114, Wroclaw, Poland
lisowski@immuno.iitd.pan.wroc.pl
SO European Cytokine Network, (July-Sept., 2001) Vol. 12, No. 3, pp. 462-467.
print.
ISSN: 1148-5493.
DT Article
LA English
ED Entered STN: 3 Jul 2002
Last Updated on STN: 3 Jul 2002

L5 ANSWER 33 OF 134 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
STN DUPLICATE 7
AN 2002:173419 BIOSIS
DN PREV200200173419
TI Towards an understanding of biological role of ***colostrinin***
peptides.
AU Kruzel, Marian L.; Janusz, Maria; Lisowski, Jozef; Fischleigh, Robert V.;
Georgiades, Jerzy A. [Reprint author]
CS ReGen Therapeutics Plc., London, UK
jerzygeorgiades@msn.com
SO Journal of Molecular Neuroscience, (December, 2001) Vol. 17, No. 3, pp.
379-389. print.
CODEN: JMNEES. ISSN: 0895-8696.
DT Article
LA English
ED Entered STN: 5 Mar 2002
Last Updated on STN: 5 Mar 2002

L5 ANSWER 34 OF 134 IMSDRUGNEWS COPYRIGHT 2004 IMSWORLD on STN DUPLICATE 8

ACCESSION NUMBER: 2000:791 IMSDRUGNEWS
TITLE: ***COLOSTRININ*** ReGen Therapeutics continues
investigation
SOURCE: R&D Focus Drug News (28 Feb 2000).
WORD COUNT: 97

L5 ANSWER 35 OF 134 USPATFULL on STN
AN 2000:94992 USPATFULL
TI B cell activation
IN Julius, Michael H., Toronto, Canada
Filipp, Dominik, Toronto, Canada
Alizadeh-Khiavi, Kame], London, Canada
PA The Wellesley Hospital Foundation, Toronto, Canada (non-U.S.
corporation)
PI US 6093693 20000725
AI US 1996-746883 19961118 (8)
DT Utility
FS Granted
LN.CNT 1392
INCL INCLM: 514/008.000
INCLS: 514/021.000; 424/185.100; 424/278.100; 530/351.000
NCL NCLM: 514/008.000
NCLS: 424/185.100; 424/278.100; 514/021.000; 530/351.000
IC [7]
ICM: A61K038-18
ICS: C07K014-475
EXF 424/185.1; 424/198.1; 424/278.1; 514/12; 514/8; 514/21; 530/351
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 36 OF 134 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
STN
AN 2000:468205 BIOSIS
DN PREV200000468205
TI A proline-rich polypeptide complex (****PRP****) and analogues of its
active nonapeptide affect induction of ***cytokines*** and reactive
oxygen species.
AU Zablocka, A. [Reprint author]; Janusz, M. [Reprint author]; Rybka, K.
[Reprint author]; Wirkus-Romanowska, I.; Miecznikowska, H.; Kupryszewski,
G.; Lisowski, J. [Reprint author]
CS Institute of Immunology and Experimental Therapy, Wroclaw, Poland
SO Immunology Letters, (September, 2000) Vol. 73, No. 2-3, pp. 223. print.
Meeting Info.: 24th European Immunology Meeting of the European Federation
of Immunological Societies (EFIS). Poznan, Poland. September 23-26, 2000.
European Federation of Immunological Societies.
CODEN: IMLED6. ISSN: 0165-2478.
DT Conference; (Meeting)
Conference; Abstract; (Meeting Abstract)
LA English
ED Entered STN: 1 Nov 2000
Last Updated on STN: 10 Jan 2002

L5 ANSWER 37 OF 134 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation.
on STN
AN 2000:126762 SCISEARCH
GA The Genuine Article (R) Number: 282HW
TI Fragments of a proline-rich polypeptide settled on a hexapeptide carcass
constructed of glycine and L-lysine residues. Synthesis and biological
properties
AU WirkusRomanowska I (Reprint); Miecznikowska H; Zablocka A; Rybka K;
Fortuna W; Miedzybrodzki R; Szymaniec S; Janusz M; Lisowski J;
Kupryszewski G
CS UNIV GDANSK, FAC CHEM, SOBIESKIEGO 18, PL-80952 GDANSK, POLAND (Reprint);
POLISH ACAD SCI, INST IMMUNOL & EXPT THERAPY, PL-53114 WROCLAW, POLAND
CYA POLAND
SO POLISH JOURNAL OF CHEMISTRY, (FEB 2000) Vol. 74, No. 2, pp. 219-225.
Publisher: POLISH CHEMICAL SOCIETY, C/O POLISH ACAD SCIENCES, INST
PHYSICAL CHEMISTRY, UL KASPRZAKA 44/52, 01-224 WARSAW, POLAND.
ISSN: 0137-5083.
DT Article; Journal
FS PHYS
LA English
REC Reference Count: 20
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L5 ANSWER 38 OF 134 USPATFULL on STN
AN 1999:159997 USPATFULL
TI Compounds that bind bacterial pili
IN Shekhani, Mohammed Saleh, Madison, WI, United States
Firca, Joseph R., Vernon Hills, IL, United States
Anderson, Byron, Morton Grove, IL, United States
PA Ophidian Pharmaceuticals, Inc., Madison, WI, United States (U.S.
corporation)
PI US 5998381 19991207
AI US 1996-760903 19961206 (8)
DT Utility
FS Granted
LN.CNT 6570
INCL INCLM: 514/025.000
INCLS: 536/004.100; 536/017.200; 536/017.900; 514/023.000
NCL NCLM: 514/025.000
NCLS: 514/023.000; 536/004.100; 536/017.200; 536/017.900
IC [6]
ICM: A61K031-70
ICS: C07H015-00; C07H017-00
EXF 519/25; 519/23; 536/17.9; 536/4.1; 536/17.2
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 39 OF 134 PASCAL COPYRIGHT 2004 INIST-CNRS. ALL RIGHTS RESERVED.
on STN DUPLICATE 9
AN 2000-0072575 PASCAL
CP Copyright .COPYRGT. 2000 INIST-CNRS. All rights reserved.
TIEN Effect of proline rich polypeptide from ovine ***colostrum*** on
virus replication in human placenta and amniotic membrane at term;
possible role of endogenous tumour necrosis factor .alpha.
AU DOMARACZENKO B.; JANUSZ M.; ORZECZOWSKA B.; JAROSZ W.; BLACH-OLSZEWSKA Z.

CS Laboratory of Virology, Institute of Immunology and Experimental Therapy,
Polish Academy of Sciences, R. Weigla 12, 53-114 Wrocław, Poland;
Department of Immunochemistry, Institute of Immunology and Experimental
Therapy, Polish Academy of Sciences, R. Weigla 12, 53-114 Wrocław,
Poland; Department of Obstetrics, Regional Hospital, Kamińskiego 73a,
51-124 Wrocław, Poland

SO Placenta : (Eastbourne), (1999), 20(8), 695-701, 16 refs.
ISSN: 0143-4004 CODEN: PLACDF

DT Journal

BL Analytic

CY United Kingdom

LA English

AV INIST-18818, 354000088289650090

L5 ANSWER 40 OF 134 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
STN DUPLICATE 10

AN 2000:162385 BIOSIS

DN PREV200000162385

TI ***Colostrinin*** (R): A proline-rich polypeptide (***PRP***)
complex isolated from ovine ***colostrum*** for treatment of
Alzheimer's disease. A double-blind, placebo-controlled study.

AU Leszek, Jerzy; Inglot, Anna D.; Janusz, Maria [Reprint author]; Lisowski,
Jozef; Krukowska, Katarzyna; Georgiades, Jerzy A.

CS Institute of Immunology and Experimental Therapy, Polish Academy of
Sciences, Weigla 12, 53-114, Wrocław, Poland

SO Archivum Immunologiae et Therapiae Experimentalis, (1999) Vol. 47, No. 6,
pp. 377-385. print.
CODEN: AITEAT. ISSN: 0004-069X.

DT Article

LA English

ED Entered STN: 26 Apr 2000
Last Updated on STN: 4 Jan 2002

L5 ANSWER 41 OF 134 ADISCTI COPYRIGHT (C) 2004 Adis Data Information BV on
STN

AN 1999:28924 ADISCTI

DN 800741417

TI ***Colostrinin*** : new treatment perspectives of Alzheimer's disease.
ADIS TITLE: ***Colostrinin*** vs selenium: therapeutic use.
Alzheimer's disease.

AU Leszek J W; Inglot A D; Lisowski J; Janusz M; Kieima A; et al.

CS University of Wrocław, Wrocław, Poland.

SO American Psychiatric Association 1999 Annual Meeting : New Research
Program & Abstracts (May 15, 1999), pp. 216

DT Study

RE Alzheimer's Disease and Cognition Disorders| Neurological Disorders

FS Summary

LA English

WC 313

L5 ANSWER 42 OF 134 PHIN COPYRIGHT 2004 PJB on STN

AN 1998:19094 PHIN

DN S00599212

DED 21 oct 1998

TI ReGen raises funds to target Alzheimer's

SO Scrip (1998) No. 2380 p11

DT Newsletter

FS FULL

L5 ANSWER 43 OF 134 SCISEARCH COPYRIGHT (c) 2004 The Thomson Corporation.
on STN

AN 1998:423418 SCISEARCH

GA The Genuine Article (R) Number: ZQ404

TI Tumor-associated antigens are ***cytokine*** inducers and
hyporeactivity factors to the immune system

AU Inglot A D; Gelder F; Georgiades J A (Reprint)

CS GEORGIADES FDN TREATMENT CHRON VIRAL DIS, STAFFORD, TX 77477 (Reprint);
GEORGIADES FDN TREATMENT CHRON VIRAL DIS, STAFFORD, TX 77477; POLISH ACAD
SCI, INST IMMUNOL & EXPT THERAPY, VIROL LAB, PL-53114 WROCLAW, POLAND;
LOUISIANA STATE UNIV, SCH MED, SHREVEPORT, LA 71130

CYA USA; POLAND

SO BIOTHERAPY, (MAY 1998) Vol. 11, No. 1, pp. 27-37.
Publisher: KLUWER ACADEMIC PUBL, SPUIBOULEVARD 50, PO BOX 17, 3300 AA
DORDRECHT, NETHERLANDS.
ISSN: 0921-299X.

DT Article; Journal
FS LIFE
LA English
REC Reference Count: 33
ABSTRACT IS AVAILABLE IN THE ALL AND IALL FORMATS

L5 ANSWER 44 OF 134 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
STN DUPLICATE 11

AN 1997:367021 BIOSIS

DN PREV199799658954

TI stimulatory effect of ovine colostrinine (a proline-rich polypeptide) on
interferons and tumor necrosis factor production by murine resident
peritoneal cells.

AU Blach-olszewska, Zofia [Reprint author]; Jansuz, Maria

CS Lab. Virology, Inst. Immunology Experimental Therapy, Polish Academy
Sciences, Weigla 12, 53-114 Wroclaw, Poland

SO Archivum Immunologiae et Therapiae Experimentalis, (1997) Vol. 45, No. 1,
pp. 43-47.

CODEN: AITEAT. ISSN: 0004-069X.

DT Article

LA English

ED Entered STN: 25 Aug 1997

Last Updated on STN: 25 Aug 1997

L5 ANSWER 45 OF 134 USPATFULL on STN

AN 96:77558 USPATFULL

TI Immunogenic anaplasma marginale surface antigens, compositions, and
methods of use

IN McGuire, Travis C., SW. 920 Crestview, Pullman, WA, United States 99163

Palmer, Guy H., NW. 335 Dillon, Pullman, WA, United States 99163

Barbet, Anthony F., 31 SW. 21st Rd., Archer, FL, United States 32618

Davis, William C., NW. 300 Yates, Pullman, WA, United States 99163

PI US 5549898 19960827

AI US 1994-228180 19940415 (8)

RLI Continuation of Ser. No. US 1993-79971, filed on 18 Jun 1993, now
abandoned which is a continuation of Ser. No. US 1992-875554, filed on
27 Apr 1992, now abandoned which is a continuation of Ser. No. US
1989-335178, filed on 6 Apr 1989, now abandoned which is a
continuation-in-part of Ser. No. US 1988-253143, filed on 4 Oct 1988,
now abandoned Ser. No. Ser. No. US 1988-245855, filed on 16 Sep 1988,
now abandoned And Ser. No. US 1988-141505, filed on 7 Jan 1988, now
abandoned which is a continuation of Ser. No. US 1985-761178, filed on 3
Jul 1985, now abandoned which is a continuation-in-part of Ser. No. US
1985-715528, filed on 25 Mar 1985, now abandoned

DT Utility

FS Granted

LN.CNT 2189

INCL INCLM: 424/269.100

INCLS: 424/265.100; 424/266.100; 424/270.100

NCL NCLM: 424/269.100

NCLS: 424/265.100; 424/266.100; 424/270.100

IC [6]

ICM: A61K039-00

ICS: A61K039-002; A61K039-005; A61K039-018

EXF 424/93.1; 424/184.1; 424/190.1; 424/269.1; 424/184.1; 424/265.1;

424/266.1; 424/270.1; 424/269.1

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L5 ANSWER 46 OF 134 BIOSIS COPYRIGHT (c) 2004 The Thomson Corporation. on
STN DUPLICATE 12

AN 1997:111129 BIOSIS

DN PREV199799410332

TI Colostrinine: A proline-rich polypeptide from ovine ***colostrum*** is
a modest ***cytokine*** inducer in human ***leukocytes***.

AU Inglot, Anna D. [Reprint author]; Janusz, Maria [Reprint author];
Lisowski, Jozef

CS Lab. Virol., Inst. Immunol. Exp. Ther., Pol. Acad. Sci., Czerska 12,
53-114 Wroclaw, Poland

SO Archivum Immunologiae et Therapiae Experimentalis, (1996) Vol. 44, No. 4,
pp. 215-224.

CODEN: AITEAT. ISSN: 0004-069X.

DT Article

LA English

ED Entered STN: 10 Mar 1997

Last Updated on STN: 10 Mar 1997

L5 ANSWER 47 OF 134 DRUGU COPYRIGHT 2004 THOMSON DERWENT on STN
AN 1997-04276 DRUGU T
TI ***Colostrinin*** - new ***cytokine*** with psycho-immuno-
enhancing activity, for treatment of Alzheimer's disease.
AU Leszek J; Inglot A D; Janusz M; Lisowski J
CS Univ.Wroclaw
LO Wroclaw, Pol.
SO J.Neural Transm. (103, No. 10, XXXIX, 1996)
CODEN: JNTMAH ISSN: 0300-9564
AV Department of Psychiatry, University of Wroclaw, Wroclaw, Poland.
LA English
DT Journal
FA AB; LA; CT
FS Literature

L5 ANSWER 48 OF 134 PHIN COPYRIGHT 2004 PJB on STN

AN 94:19233 PHIN
DN P00422818
DED 11 Nov 1994
TI Vaccine research breaks new ground
SO Animal-Pharm (1994) No. 312 p20
DT Newsletter
FS FULL

L5 ANSWER 49 OF 134 ADISINSIGHT COPYRIGHT (C) 2004 Adis Data Information BV
on STN

ACCESSION NUMBER: 2000:995 ADISINSIGHT
SOURCE: Adis R&D Insight
DOCUMENT NO: 014121
CHANGE DATE: Apr 5, 2004
GENERIC NAME: ***Colostrinin***
MOLECULAR FORMULA:Unspecified
STRUCTURE:

STRUCTURE DIAGRAM IS NOT AVAILABLE

EPHMRA ATC CODE: N7D9 All other anti-Alzheimer products
WHO ATC CODE: N06D-X Other anti-dementia drugs
HIGHEST DEV. PHASE: Phase II

COMPANY INFORMATION

ORIGINATOR: Nonindustrial source (Poland); Nonindustrial source
(Unknown)
PARENT: Nonindustrial source
LICENSEE: ReGen Therapeutics

OTHER SOURCES: 800741417; 809026793
WORD COUNT: 613

L5 ANSWER 50 OF 134 BIOCOMMERCE COPYRIGHT 2004 BioCommerce Data Ltd. on STN

AN 1046113 BIOCOMMERCE FS Directory
CO ReGen Therapeutics Plc (46652)
CA 4th Floor, Suite 406, Langham House
29-30 Margaret Street
W1W 8SA London
UK

TL Telephone: (020) 79070910
Telefax: (020) 79070911
E-mail: head.office@regentherapeutics.com
URL: <http://www.regentherapeutics.com>

L5 ANSWER 51 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN

AN ABG32223 peptide DGENE
TI Novel peptides isolated from ***colostrinin*** polypeptide, useful
for treating viral and bacterial infections, disorders of immune system
and central nervous system e.g., Alzheimer's disease, dementia, and as
food additive -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002046211 A2 20020613 16p
AI WO 2001-GB5376 20011205
PRAI GB 2000-29777 20001206
DT Patent
LA English
OS 2002-619016 [66]

DESC Sheep ***colostrinin*** derived peptide #17.

L5 ANSWER 52 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ABG32222 peptide DGENE
TI Novel peptides isolated from ***colostrinin*** polypeptide, useful
for treating viral and bacterial infections, disorders of immune system
and central nervous system e.g., Alzheimer's disease, dementia, and as
food additive -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002046211 A2 20020613 16p
AI WO 2001-GB5376 20011205
PRAI GB 2000-29777 20001206
DT Patent
LA English
OS 2002-619016 [66]

DESC Sheep ***colostrinin*** derived peptide #16.

L5 ANSWER 53 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ABG32221 peptide DGENE
TI Novel peptides isolated from ***colostrinin*** polypeptide, useful
for treating viral and bacterial infections, disorders of immune system
and central nervous system e.g., Alzheimer's disease, dementia, and as
food additive -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002046211 A2 20020613 16p
AI WO 2001-GB5376 20011205
PRAI GB 2000-29777 20001206
DT Patent
LA English
OS 2002-619016 [66]

DESC Sheep ***colostrinin*** derived peptide #15.

L5 ANSWER 54 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ABG32220 peptide DGENE
TI Novel peptides isolated from ***colostrinin*** polypeptide, useful
for treating viral and bacterial infections, disorders of immune system
and central nervous system e.g., Alzheimer's disease, dementia, and as
food additive -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002046211 A2 20020613 16p
AI WO 2001-GB5376 20011205
PRAI GB 2000-29777 20001206
DT Patent
LA English
OS 2002-619016 [66]

DESC Sheep ***colostrinin*** derived peptide #14.

L5 ANSWER 55 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ABG32219 peptide DGENE
TI Novel peptides isolated from ***colostrinin*** polypeptide, useful
for treating viral and bacterial infections, disorders of immune system
and central nervous system e.g., Alzheimer's disease, dementia, and as
food additive -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002046211 A2 20020613 16p
AI WO 2001-GB5376 20011205
PRAI GB 2000-29777 20001206
DT Patent
LA English
OS 2002-619016 [66]

DESC Sheep ***colostrinin*** derived peptide #13.

L5 ANSWER 56 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ABG32218 peptide DGENE
TI Novel peptides isolated from ***colostrinin*** polypeptide, useful
for treating viral and bacterial infections, disorders of immune system
and central nervous system e.g., Alzheimer's disease, dementia, and as
food additive -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002046211 A2 20020613 16p
AI WO 2001-GB5376 20011205

PRAI GB 2000-29777 20001206
DT Patent
LA English
OS 2002-619016 [66]
DESC Sheep ***colostrinin*** derived peptide #12.

L5 ANSWER 57 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ABG32217 peptide DGENE
TI Novel peptides isolated from ***colostrinin*** polypeptide, useful
for treating viral and bacterial infections, disorders of immune system
and central nervous system e.g., Alzheimer's disease, dementia, and as
food additive -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002046211 A2 20020613 16p
AI WO 2001-GB5376 20011205
PRAI GB 2000-29777 20001206
DT Patent
LA English
OS 2002-619016 [66]
DESC Sheep ***colostrinin*** derived peptide #11.

L5 ANSWER 58 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ABG32216 peptide DGENE
TI Novel peptides isolated from ***colostrinin*** polypeptide, useful
for treating viral and bacterial infections, disorders of immune system
and central nervous system e.g., Alzheimer's disease, dementia, and as
food additive -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002046211 A2 20020613 16p
AI WO 2001-GB5376 20011205
PRAI GB 2000-29777 20001206
DT Patent
LA English
OS 2002-619016 [66]
DESC Sheep ***colostrinin*** derived peptide #10.

L5 ANSWER 59 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ABG32215 peptide DGENE
TI Novel peptides isolated from ***colostrinin*** polypeptide, useful
for treating viral and bacterial infections, disorders of immune system
and central nervous system e.g., Alzheimer's disease, dementia, and as
food additive -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002046211 A2 20020613 16p
AI WO 2001-GB5376 20011205
PRAI GB 2000-29777 20001206
DT Patent
LA English
OS 2002-619016 [66]
DESC Sheep ***colostrinin*** derived peptide #9.

L5 ANSWER 60 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ABG32214 peptide DGENE
TI Novel peptides isolated from ***colostrinin*** polypeptide, useful
for treating viral and bacterial infections, disorders of immune system
and central nervous system e.g., Alzheimer's disease, dementia, and as
food additive -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002046211 A2 20020613 16p
AI WO 2001-GB5376 20011205
PRAI GB 2000-29777 20001206
DT Patent
LA English
OS 2002-619016 [66]
DESC Sheep ***colostrinin*** derived peptide #8.

L5 ANSWER 61 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ABG32213 peptide DGENE
TI Novel peptides isolated from ***colostrinin*** polypeptide, useful
for treating viral and bacterial infections, disorders of immune system
and central nervous system e.g., Alzheimer's disease, dementia, and as
food additive -

IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002046211 A2 20020613 16p
AI WO 2001-GB5376 20011205
PRAI GB 2000-29777 20001206
DT Patent
LA English
OS 2002-619016 [66]
DESC Sheep ***colostrinin*** derived peptide #7.

L5 ANSWER 62 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ABG32212 peptide DGENE
TI Novel peptides isolated from ***colostrinin*** polypeptide, useful
for treating viral and bacterial infections, disorders of immune system
and central nervous system e.g., Alzheimer's disease, dementia, and as
food additive -

IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002046211 A2 20020613 16p
AI WO 2001-GB5376 20011205
PRAI GB 2000-29777 20001206
DT Patent
LA English
OS 2002-619016 [66]
DESC Sheep ***colostrinin*** derived peptide #6.

L5 ANSWER 63 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ABG32211 peptide DGENE
TI Novel peptides isolated from ***colostrinin*** polypeptide, useful
for treating viral and bacterial infections, disorders of immune system
and central nervous system e.g., Alzheimer's disease, dementia, and as
food additive -

IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002046211 A2 20020613 16p
AI WO 2001-GB5376 20011205
PRAI GB 2000-29777 20001206
DT Patent
LA English
OS 2002-619016 [66]
DESC Sheep ***colostrinin*** derived peptide #5.

L5 ANSWER 64 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ABG32210 peptide DGENE
TI Novel peptides isolated from ***colostrinin*** polypeptide, useful
for treating viral and bacterial infections, disorders of immune system
and central nervous system e.g., Alzheimer's disease, dementia, and as
food additive -

IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002046211 A2 20020613 16p
AI WO 2001-GB5376 20011205
PRAI GB 2000-29777 20001206
DT Patent
LA English
OS 2002-619016 [66]
DESC Sheep ***colostrinin*** derived peptide #4.

L5 ANSWER 65 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ABG32209 peptide DGENE
TI Novel peptides isolated from ***colostrinin*** polypeptide, useful
for treating viral and bacterial infections, disorders of immune system
and central nervous system e.g., Alzheimer's disease, dementia, and as
food additive -

IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002046211 A2 20020613 16p
AI WO 2001-GB5376 20011205
PRAI GB 2000-29777 20001206
DT Patent
LA English
OS 2002-619016 [66]
DESC Sheep ***colostrinin*** derived peptide #3.

L5 ANSWER 66 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ABG32208 peptide DGENE

TI Novel peptides isolated from ***colostrinin*** polypeptide, useful for treating viral and bacterial infections, disorders of immune system and central nervous system e.g., Alzheimer's disease, dementia, and as food additive -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002046211 A2 20020613 16p
AI WO 2001-GB5376 20011205
PRAI GB 2000-29777 20001206
DT Patent
LA English
OS 2002-619016 [66]
DESC Sheep ***colostrinin*** derived peptide #2.

L5 ANSWER 67 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN ABG32207 peptide DGENE
TI Novel peptides isolated from ***colostrinin*** polypeptide, useful for treating viral and bacterial infections, disorders of immune system and central nervous system e.g., Alzheimer's disease, dementia, and as food additive -
IN Georgiades J A
PA (REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002046211 A2 20020613 16p
AI WO 2001-GB5376 20011205
PRAI GB 2000-29777 20001206
DT Patent
LA English
OS 2002-619016 [66]
DESC Sheep ***colostrinin*** derived peptide #1.

L5 ANSWER 68 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAM51066 Peptide DGENE
TI Modulation of blood cell proliferation in a patient involves use of blood cell regulator selected from ***colostrinin***, its constituent peptide and/or analogue -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002013849 A1 20020221 54p
AI WO 2000-US22775 20000817
PRAI WO 2000-US22775 20000817
DT Patent
LA English
OS 2002-269150 [31]
DESC ***Colostrinin*** constituent peptide (casein amino acids 159-173).

L5 ANSWER 69 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAM51065 Peptide DGENE
TI Modulation of blood cell proliferation in a patient involves use of blood cell regulator selected from ***colostrinin***, its constituent peptide and/or analogue -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002013849 A1 20020221 54p
AI WO 2000-US22775 20000817
PRAI WO 2000-US22775 20000817
DT Patent
LA English
OS 2002-269150 [31]
DESC ***Colostrinin*** constituent peptide (casein amino acids 203-214).

L5 ANSWER 70 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAM51064 Peptide DGENE
TI Modulation of blood cell proliferation in a patient involves use of blood cell regulator selected from ***colostrinin***, its constituent peptide and/or analogue -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002013849 A1 20020221 54p
AI WO 2000-US22775 20000817
PRAI WO 2000-US22775 20000817
DT Patent
LA English
OS 2002-269150 [31]

DESC ***Colostrinin*** constituent peptide (annexin amino acids 203-220).

L5 ANSWER 71 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAM51063 Peptide DGENE
TI Modulation of blood cell proliferation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analogue -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002013849 A1 20020221 54p
AI WO 2000-US22775 20000817
PRAI WO 2000-US22775 20000817
DT Patent
LA English
OS 2002-269150 [31]
DESC ***Colostrinin*** constituent peptide (casein amino acids 214-222).

L5 ANSWER 72 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAM51062 Peptide DGENE
TI Modulation of blood cell proliferation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analogue -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002013849 A1 20020221 54p
AI WO 2000-US22775 20000817
PRAI WO 2000-US22775 20000817
DT Patent
LA English
OS 2002-269150 [31]
DESC ***Colostrinin*** constituent peptide (casein amino acids 202-208).

L5 ANSWER 73 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAM51061 Peptide DGENE
TI Modulation of blood cell proliferation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analogue -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002013849 A1 20020221 54p
AI WO 2000-US22775 20000817
PRAI WO 2000-US22775 20000817
DT Patent
LA English
OS 2002-269150 [31]
DESC ***Colostrinin*** constituent peptide (casein amino acids 180-201).

L5 ANSWER 74 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAM51060 Peptide DGENE
TI Modulation of blood cell proliferation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analogue -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002013849 A1 20020221 54p
AI WO 2000-US22775 20000817
PRAI WO 2000-US22775 20000817
DT Patent
LA English
OS 2002-269150 [31]
DESC ***Colostrinin*** constituent peptide (casein amino acids 174-179).

L5 ANSWER 75 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAM51059 Peptide DGENE
TI Modulation of blood cell proliferation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analogue -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002013849 A1 20020221 54p
AI WO 2000-US22775 20000817

PRAI WO 2000-US22775 20000817
 DT Patent
 LA English
 OS 2002-269150 [31]
 DESC ***Colostrinin*** constituent peptide (casein amino acids 164-173).

L5 ANSWER 76 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAM51058 Peptide DGENE
 TI Modulation of blood cell proliferation in a patient involves use of blood cell regulator selected from ***colostrinin***, its constituent peptide and/or analogue -
 IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
 PA (TEXA) UNIV TEXAS SYSTEM.
 (REGE-N) REGEN THERAPEUTICS PLC.
 PI WO 2002013849 A1 20020221 54p
 AI WO 2000-US22775 20000817
 PRAI WO 2000-US22775 20000817
 DT Patent
 LA English
 OS 2002-269150 [31]
 DESC ***Colostrinin*** constituent peptide (casein amino acids 157-163).

L5 ANSWER 77 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAM51057 Peptide DGENE
 TI Modulation of blood cell proliferation in a patient involves use of blood cell regulator selected from ***colostrinin***, its constituent peptide and/or analogue -
 IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
 PA (TEXA) UNIV TEXAS SYSTEM.
 (REGE-N) REGEN THERAPEUTICS PLC.
 PI WO 2002013849 A1 20020221 54p
 AI WO 2000-US22775 20000817
 PRAI WO 2000-US22775 20000817
 DT Patent
 LA English
 OS 2002-269150 [31]
 DESC ***Colostrinin*** constituent peptide (casein amino acids 139-156).

L5 ANSWER 78 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAM51056 Peptide DGENE
 TI Modulation of blood cell proliferation in a patient involves use of blood cell regulator selected from ***colostrinin***, its constituent peptide and/or analogue -
 IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
 PA (TEXA) UNIV TEXAS SYSTEM.
 (REGE-N) REGEN THERAPEUTICS PLC.
 PI WO 2002013849 A1 20020221 54p
 AI WO 2000-US22775 20000817
 PRAI WO 2000-US22775 20000817
 DT Patent
 LA English
 OS 2002-269150 [31]
 DESC ***Colostrinin*** constituent peptide (casein amino acids 121-138).

L5 ANSWER 79 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAM51055 Peptide DGENE
 TI Modulation of blood cell proliferation in a patient involves use of blood cell regulator selected from ***colostrinin***, its constituent peptide and/or analogue -
 IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
 PA (TEXA) UNIV TEXAS SYSTEM.
 (REGE-N) REGEN THERAPEUTICS PLC.
 PI WO 2002013849 A1 20020221 54p
 AI WO 2000-US22775 20000817
 PRAI WO 2000-US22775 20000817
 DT Patent
 LA English
 OS 2002-269150 [31]
 DESC ***Colostrinin*** constituent peptide (casein amino acids 103-120).

L5 ANSWER 80 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAM51054 Peptide DGENE
 TI Modulation of blood cell proliferation in a patient involves use of blood cell regulator selected from ***colostrinin***, its constituent peptide and/or analogue -
 IN Stanton G J; Hughes T K; Boldogh I; Georgiades J

PA (TEXA) UNIV TEXAS SYSTEM.
 (REGE-N) REGEN THERAPEUTICS PLC.
 PI WO 2002013849 A1 20020221 54p
 AI WO 2000-US22775 20000817
 PRAI WO 2000-US22775 20000817
 DT Patent
 LA English
 OS 2002-269150 [31]
 DESC ***Colostrinin*** constituent peptide (casein amino acids 93-102).

L5 ANSWER 81 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAM51053 Peptide DGENE
 TI Modulation of blood cell proliferation in a patient involves use of blood cell regulator selected from ***colostrinin***, its constituent peptide and/or analogue -
 IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
 PA (TEXA) UNIV TEXAS SYSTEM.
 (REGE-N) REGEN THERAPEUTICS PLC.
 PI WO 2002013849 A1 20020221 54p
 AI WO 2000-US22775 20000817
 PRAI WO 2000-US22775 20000817
 DT Patent
 LA English
 OS 2002-269150 [31]
 DESC ***Colostrinin*** constituent peptide (casein amino acids 84-92).

L5 ANSWER 82 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAM51052 Peptide DGENE
 TI Modulation of blood cell proliferation in a patient involves use of blood cell regulator selected from ***colostrinin***, its constituent peptide and/or analogue -
 IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
 PA (TEXA) UNIV TEXAS SYSTEM.
 (REGE-N) REGEN THERAPEUTICS PLC.
 PI WO 2002013849 A1 20020221 54p
 AI WO 2000-US22775 20000817
 PRAI WO 2000-US22775 20000817
 DT Patent
 LA English
 OS 2002-269150 [31]
 DESC ***Colostrinin*** constituent peptide (casein amino acids 74-83).

L5 ANSWER 83 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAM51051 Peptide DGENE
 TI Modulation of blood cell proliferation in a patient involves use of blood cell regulator selected from ***colostrinin***, its constituent peptide and/or analogue -
 IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
 PA (TEXA) UNIV TEXAS SYSTEM.
 (REGE-N) REGEN THERAPEUTICS PLC.
 PI WO 2002013849 A1 20020221 54p
 AI WO 2000-US22775 20000817
 PRAI WO 2000-US22775 20000817
 DT Patent
 LA English
 OS 2002-269150 [31]
 DESC ***Colostrinin*** constituent peptide.

L5 ANSWER 84 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAM51050 Peptide DGENE
 TI Modulation of blood cell proliferation in a patient involves use of blood cell regulator selected from ***colostrinin***, its constituent peptide and/or analogue -
 IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
 PA (TEXA) UNIV TEXAS SYSTEM.
 (REGE-N) REGEN THERAPEUTICS PLC.
 PI WO 2002013849 A1 20020221 54p
 AI WO 2000-US22775 20000817
 PRAI WO 2000-US22775 20000817
 DT Patent
 LA English
 OS 2002-269150 [31]
 DESC ***Colostrinin*** constituent peptide.

L5 ANSWER 85 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAM51049 Peptide DGENE

TI Modulation of blood cell proliferation in a patient involves use of blood
cell regulator selected from ***colostrinin*** , its constituent
peptide and/or analogue -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002013849 A1 20020221 54p
AI WO 2000-US22775 20000817
PRAI WO 2000-US22775 20000817
DT Patent
LA English
OS 2002-269150 [31]
DESC ***Colostrinin*** constituent peptide.

L5 ANSWER 86 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAM51048 Peptide DGENE
TI Modulation of blood cell proliferation in a patient involves use of blood
cell regulator selected from ***colostrinin*** , its constituent
peptide and/or analogue -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002013849 A1 20020221 54p
AI WO 2000-US22775 20000817
PRAI WO 2000-US22775 20000817
DT Patent
LA English
OS 2002-269150 [31]
DESC ***Colostrinin*** constituent peptide.

L5 ANSWER 87 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAM51047 Peptide DGENE
TI Modulation of blood cell proliferation in a patient involves use of blood
cell regulator selected from ***colostrinin*** , its constituent
peptide and/or analogue -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002013849 A1 20020221 54p
AI WO 2000-US22775 20000817
PRAI WO 2000-US22775 20000817
DT Patent
LA English
OS 2002-269150 [31]
DESC ***Colostrinin*** constituent peptide.

L5 ANSWER 88 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAM51046 Peptide DGENE
TI Modulation of blood cell proliferation in a patient involves use of blood
cell regulator selected from ***colostrinin*** , its constituent
peptide and/or analogue -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002013849 A1 20020221 54p
AI WO 2000-US22775 20000817
PRAI WO 2000-US22775 20000817
DT Patent
LA English
OS 2002-269150 [31]
DESC ***Colostrinin*** constituent peptide.

L5 ANSWER 89 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAM51045 Peptide DGENE
TI Modulation of blood cell proliferation in a patient involves use of blood
cell regulator selected from ***colostrinin*** , its constituent
peptide and/or analogue -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002013849 A1 20020221 54p
AI WO 2000-US22775 20000817
PRAI WO 2000-US22775 20000817
DT Patent
LA English
OS 2002-269150 [31]

DESC ***Colostrinin*** constituent peptide.

L5 ANSWER 90 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAM51044 Peptide DGENE
TI Modulation of blood cell proliferation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analogue -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002013849 A1 20020221 54p
AI WO 2000-US22775 20000817
PRAI WO 2000-US22775 20000817
DT Patent
LA English
OS 2002-269150 [31]
DESC ***Colostrinin*** constituent peptide.

L5 ANSWER 91 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAM51043 Peptide DGENE
TI Modulation of blood cell proliferation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analogue -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002013849 A1 20020221 54p
AI WO 2000-US22775 20000817
PRAI WO 2000-US22775 20000817
DT Patent
LA English
OS 2002-269150 [31]
DESC ***Colostrinin*** constituent peptide.

L5 ANSWER 92 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAM51042 Peptide DGENE
TI Modulation of blood cell proliferation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analogue -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002013849 A1 20020221 54p
AI WO 2000-US22775 20000817
PRAI WO 2000-US22775 20000817
DT Patent
LA English
OS 2002-269150 [31]
DESC ***Colostrinin*** constituent peptide.

L5 ANSWER 93 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAM51041 Peptide DGENE
TI Modulation of blood cell proliferation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analogue -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002013849 A1 20020221 54p
AI WO 2000-US22775 20000817
PRAI WO 2000-US22775 20000817
DT Patent
LA English
OS 2002-269150 [31]
DESC ***Colostrinin*** constituent peptide.

L5 ANSWER 94 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAM51040 Peptide DGENE
TI Modulation of blood cell proliferation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analogue -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2002013849 A1 20020221 54p
AI WO 2000-US22775 20000817

PRAI WO 2000-US22775 20000817
 DT Patent
 LA English
 OS 2002-269150 [31]
 DESC ***Colostrinin*** constituent peptide.

L5 ANSWER 95 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAM51039 Peptide DGENE
 TI Modulation of blood cell proliferation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analogue -
 IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
 PA (TEXA) UNIV TEXAS SYSTEM.
 (REGE-N) REGEN THERAPEUTICS PLC.
 PI WO 2002013849 A1 20020221 54p
 AI WO 2000-US22775 20000817
 PRAI WO 2000-US22775 20000817
 DT Patent
 LA English
 OS 2002-269150 [31]
 DESC ***Colostrinin*** constituent peptide.

L5 ANSWER 96 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAM51038 Peptide DGENE
 TI Modulation of blood cell proliferation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analogue -
 IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
 PA (TEXA) UNIV TEXAS SYSTEM.
 (REGE-N) REGEN THERAPEUTICS PLC.
 PI WO 2002013849 A1 20020221 54p
 AI WO 2000-US22775 20000817
 PRAI WO 2000-US22775 20000817
 DT Patent
 LA English
 OS 2002-269150 [31]
 DESC ***Colostrinin*** constituent peptide.

L5 ANSWER 97 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAM51037 Peptide DGENE
 TI Modulation of blood cell proliferation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analogue -
 IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
 PA (TEXA) UNIV TEXAS SYSTEM.
 (REGE-N) REGEN THERAPEUTICS PLC.
 PI WO 2002013849 A1 20020221 54p
 AI WO 2000-US22775 20000817
 PRAI WO 2000-US22775 20000817
 DT Patent
 LA English
 OS 2002-269150 [31]
 DESC ***Colostrinin*** constituent peptide.

L5 ANSWER 98 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAM51036 Peptide DGENE
 TI Modulation of blood cell proliferation in a patient involves use of blood cell regulator selected from ***colostrinin*** , its constituent peptide and/or analogue -
 IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
 PA (TEXA) UNIV TEXAS SYSTEM.
 (REGE-N) REGEN THERAPEUTICS PLC.
 PI WO 2002013849 A1 20020221 54p
 AI WO 2000-US22775 20000817
 PRAI WO 2000-US22775 20000817
 DT Patent
 LA English
 OS 2002-269150 [31]
 DESC ***Colostrinin*** constituent peptide.

L5 ANSWER 99 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAB72279 peptide DGENE
 TI Inducing a ***cytokine*** and modulating an immune response, useful for treating central nervous system diseases and bacterial and viral infections, comprises administering ***colostrinin*** as an immunological regulator -

IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001011937 A2 20010222 50p
AI WO 2000-US22818 20000817
PRAI US 1999-149311 19990817
DT Patent
LA English
OS 2001-202804 [20]
DESC ***Colostrinin*** derived ***cytokine*** inducing peptide SEQ ID
34.

L5 ANSWER 100 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB72278 peptide DGENE
TI Inducing a ***cytokine*** and modulating an immune response, useful
for treating central nervous system diseases and bacterial and viral
infections, comprises administering ***colostrinin*** as an
immunological regulator -

IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001011937 A2 20010222 50p
AI WO 2000-US22818 20000817
PRAI US 1999-149311 19990817
DT Patent
LA English
OS 2001-202804 [20]
DESC ***Colostrinin*** derived ***cytokine*** inducing peptide SEQ ID
33.

L5 ANSWER 101 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB72277 peptide DGENE
TI Inducing a ***cytokine*** and modulating an immune response, useful
for treating central nervous system diseases and bacterial and viral
infections, comprises administering ***colostrinin*** as an
immunological regulator -

IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001011937 A2 20010222 50p
AI WO 2000-US22818 20000817
PRAI US 1999-149311 19990817
DT Patent
LA English
OS 2001-202804 [20]
DESC ***Colostrinin*** derived ***cytokine*** inducing peptide SEQ ID
32.

L5 ANSWER 102 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB72276 peptide DGENE
TI Inducing a ***cytokine*** and modulating an immune response, useful
for treating central nervous system diseases and bacterial and viral
infections, comprises administering ***colostrinin*** as an
immunological regulator -

IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001011937 A2 20010222 50p
AI WO 2000-US22818 20000817
PRAI US 1999-149311 19990817
DT Patent
LA English
OS 2001-202804 [20]
DESC ***Colostrinin*** derived ***cytokine*** inducing peptide SEQ ID
31.

L5 ANSWER 103 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB72275 peptide DGENE
TI Inducing a ***cytokine*** and modulating an immune response, useful
for treating central nervous system diseases and bacterial and viral
infections, comprises administering ***colostrinin*** as an
immunological regulator -

IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001011937 A2 20010222 50p

AI WO 2000-US22818 20000817
PRAI US 1999-149311 19990817
DT Patent
LA English
OS 2001-202804 [20]
DESC ***Colostrinin*** derived ***cytokine*** inducing peptide SEQ ID
30.

L5 ANSWER 104 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB72274 peptide DGENE
TI Inducing a ***cytokine*** and modulating an immune response, useful
for treating central nervous system diseases and bacterial and viral
infections, comprises administering ***colostrinin*** as an
immunological regulator -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001011937 A2 20010222 50p
AI WO 2000-US22818 20000817
PRAI US 1999-149311 19990817
DT Patent
LA English
OS 2001-202804 [20]
DESC ***Colostrinin*** derived ***cytokine*** inducing peptide SEQ ID
29.

L5 ANSWER 105 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB72273 peptide DGENE
TI Inducing a ***cytokine*** and modulating an immune response, useful
for treating central nervous system diseases and bacterial and viral
infections, comprises administering ***colostrinin*** as an
immunological regulator -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001011937 A2 20010222 50p
AI WO 2000-US22818 20000817
PRAI US 1999-149311 19990817
DT Patent
LA English
OS 2001-202804 [20]
DESC ***Colostrinin*** derived ***cytokine*** inducing peptide SEQ ID
28.

L5 ANSWER 106 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB72272 peptide DGENE
TI Inducing a ***cytokine*** and modulating an immune response, useful
for treating central nervous system diseases and bacterial and viral
infections, comprises administering ***colostrinin*** as an
immunological regulator -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001011937 A2 20010222 50p
AI WO 2000-US22818 20000817
PRAI US 1999-149311 19990817
DT Patent
LA English
OS 2001-202804 [20]
DESC ***Colostrinin*** derived ***cytokine*** inducing peptide SEQ ID
27.

L5 ANSWER 107 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB72271 peptide DGENE
TI Inducing a ***cytokine*** and modulating an immune response, useful
for treating central nervous system diseases and bacterial and viral
infections, comprises administering ***colostrinin*** as an
immunological regulator -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001011937 A2 20010222 50p
AI WO 2000-US22818 20000817
PRAI US 1999-149311 19990817
DT Patent
LA English

OS 2001-202804 [20]
DESC ***Colostrinin*** derived ***cytokine*** inducing peptide SEQ ID
26.

L5 ANSWER 108 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB72270 peptide DGENE
TI Inducing a ***cytokine*** and modulating an immune response, useful
for treating central nervous system diseases and bacterial and viral
infections, comprises administering ***colostrinin*** as an
immunological regulator -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001011937 A2 20010222 50p
AI WO 2000-US22818 20000817
PRAI US 1999-149311 19990817
DT Patent
LA English
OS 2001-202804 [20]
DESC ***Colostrinin*** derived ***cytokine*** inducing peptide SEQ ID
25.

L5 ANSWER 109 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB72269 peptide DGENE
TI Inducing a ***cytokine*** and modulating an immune response, useful
for treating central nervous system diseases and bacterial and viral
infections, comprises administering ***colostrinin*** as an
immunological regulator -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001011937 A2 20010222 50p
AI WO 2000-US22818 20000817
PRAI US 1999-149311 19990817
DT Patent
LA English
OS 2001-202804 [20]
DESC ***Colostrinin*** derived ***cytokine*** inducing peptide SEQ ID
24.

L5 ANSWER 110 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB72268 peptide DGENE
TI Inducing a ***cytokine*** and modulating an immune response, useful
for treating central nervous system diseases and bacterial and viral
infections, comprises administering ***colostrinin*** as an
immunological regulator -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001011937 A2 20010222 50p
AI WO 2000-US22818 20000817
PRAI US 1999-149311 19990817
DT Patent
LA English
OS 2001-202804 [20]
DESC ***Colostrinin*** derived ***cytokine*** inducing peptide SEQ ID
23.

L5 ANSWER 111 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB72267 peptide DGENE
TI Inducing a ***cytokine*** and modulating an immune response, useful
for treating central nervous system diseases and bacterial and viral
infections, comprises administering ***colostrinin*** as an
immunological regulator -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001011937 A2 20010222 50p
AI WO 2000-US22818 20000817
PRAI US 1999-149311 19990817
DT Patent
LA English
OS 2001-202804 [20]
DESC ***Colostrinin*** derived ***cytokine*** inducing peptide SEQ ID
22.

L5 ANSWER 112 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAB72266 peptide DGENE
 TI Inducing a ***cytokine*** and modulating an immune response, useful
 for treating central nervous system diseases and bacterial and viral
 infections, comprises administering ***colostrinin*** as an
 immunological regulator -
 IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
 PA (TEXA) UNIV TEXAS SYSTEM.
 (REGE-N) REGEN THERAPEUTICS PLC.
 PI WO 2001011937 A2 20010222 50p
 AI WO 2000-US22818 20000817
 PRAI US 1999-149311 19990817
 DT Patent
 LA English
 OS 2001-202804 [20]
 DESC ***Colostrinin*** derived ***cytokine*** inducing peptide SEQ ID
 21.

L5 ANSWER 113 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAB72265 peptide DGENE
 TI Inducing a ***cytokine*** and modulating an immune response, useful
 for treating central nervous system diseases and bacterial and viral
 infections, comprises administering ***colostrinin*** as an
 immunological regulator -
 IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
 PA (TEXA) UNIV TEXAS SYSTEM.
 (REGE-N) REGEN THERAPEUTICS PLC.
 PI WO 2001011937 A2 20010222 50p
 AI WO 2000-US22818 20000817
 PRAI US 1999-149311 19990817
 DT Patent
 LA English
 OS 2001-202804 [20]
 DESC ***Colostrinin*** derived ***cytokine*** inducing peptide SEQ ID
 20.

L5 ANSWER 114 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAB72264 peptide DGENE
 TI Inducing a ***cytokine*** and modulating an immune response, useful
 for treating central nervous system diseases and bacterial and viral
 infections, comprises administering ***colostrinin*** as an
 immunological regulator -
 IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
 PA (TEXA) UNIV TEXAS SYSTEM.
 (REGE-N) REGEN THERAPEUTICS PLC.
 PI WO 2001011937 A2 20010222 50p
 AI WO 2000-US22818 20000817
 PRAI US 1999-149311 19990817
 DT Patent
 LA English
 OS 2001-202804 [20]
 DESC ***Colostrinin*** derived ***cytokine*** inducing peptide SEQ ID
 19.

L5 ANSWER 115 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAB72263 peptide DGENE
 TI Inducing a ***cytokine*** and modulating an immune response, useful
 for treating central nervous system diseases and bacterial and viral
 infections, comprises administering ***colostrinin*** as an
 immunological regulator -
 IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
 PA (TEXA) UNIV TEXAS SYSTEM.
 (REGE-N) REGEN THERAPEUTICS PLC.
 PI WO 2001011937 A2 20010222 50p
 AI WO 2000-US22818 20000817
 PRAI US 1999-149311 19990817
 DT Patent
 LA English
 OS 2001-202804 [20]
 DESC ***Colostrinin*** derived ***cytokine*** inducing peptide SEQ ID
 18.

L5 ANSWER 116 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAB72262 peptide DGENE
 TI Inducing a ***cytokine*** and modulating an immune response, useful
 for treating central nervous system diseases and bacterial and viral

infections, comprises administering ***colostrinin*** as an immunological regulator -
 IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
 PA (TEXA) UNIV TEXAS SYSTEM.
 (REGE-N) REGEN THERAPEUTICS PLC.
 PI WO 2001011937 A2 20010222 50p
 AI WO 2000-US22818 20000817
 PRAI US 1999-149311 19990817
 DT Patent
 LA English
 OS 2001-202804 [20]
 DESC ***Colostrinin*** derived ***cytokine*** inducing peptide SEQ ID 17.

L5 ANSWER 117 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAB72261 peptide DGENE
 TI Inducing a ***cytokine*** and modulating an immune response, useful for treating central nervous system diseases and bacterial and viral infections, comprises administering ***colostrinin*** as an immunological regulator -
 IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
 PA (TEXA) UNIV TEXAS SYSTEM.
 (REGE-N) REGEN THERAPEUTICS PLC.
 PI WO 2001011937 A2 20010222 50p
 AI WO 2000-US22818 20000817
 PRAI US 1999-149311 19990817
 DT Patent
 LA English
 OS 2001-202804 [20]
 DESC ***Colostrinin*** derived ***cytokine*** inducing peptide SEQ ID 16.

L5 ANSWER 118 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAB72260 peptide DGENE
 TI Inducing a ***cytokine*** and modulating an immune response, useful for treating central nervous system diseases and bacterial and viral infections, comprises administering ***colostrinin*** as an immunological regulator -
 IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
 PA (TEXA) UNIV TEXAS SYSTEM.
 (REGE-N) REGEN THERAPEUTICS PLC.
 PI WO 2001011937 A2 20010222 50p
 AI WO 2000-US22818 20000817
 PRAI US 1999-149311 19990817
 DT Patent
 LA English
 OS 2001-202804 [20]
 DESC ***Colostrinin*** derived ***cytokine*** inducing peptide SEQ ID 15.

L5 ANSWER 119 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAB72259 peptide DGENE
 TI Inducing a ***cytokine*** and modulating an immune response, useful for treating central nervous system diseases and bacterial and viral infections, comprises administering ***colostrinin*** as an immunological regulator -
 IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
 PA (TEXA) UNIV TEXAS SYSTEM.
 (REGE-N) REGEN THERAPEUTICS PLC.
 PI WO 2001011937 A2 20010222 50p
 AI WO 2000-US22818 20000817
 PRAI US 1999-149311 19990817
 DT Patent
 LA English
 OS 2001-202804 [20]
 DESC ***Colostrinin*** derived ***cytokine*** inducing peptide SEQ ID 14.

L5 ANSWER 120 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
 AN AAB72258 peptide DGENE
 TI Inducing a ***cytokine*** and modulating an immune response, useful for treating central nervous system diseases and bacterial and viral infections, comprises administering ***colostrinin*** as an immunological regulator -
 IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
 PA (TEXA) UNIV TEXAS SYSTEM.

(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001011937 A2 20010222 50p
AI WO 2000-US22818 20000817
PRAI US 1999-149311 19990817
DT Patent
LA English
OS 2001-202804 [20]
DESC ***Colostrinin*** derived ***cytokine*** inducing peptide SEQ ID
13.

L5 ANSWER 121 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB72257 peptide DGENE
TI Inducing a ***cytokine*** and modulating an immune response, useful
for treating central nervous system diseases and bacterial and viral
infections, comprises administering ***colostrinin*** as an
immunological regulator -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001011937 A2 20010222 50p
AI WO 2000-US22818 20000817
PRAI US 1999-149311 19990817
DT Patent
LA English
OS 2001-202804 [20]
DESC ***Colostrinin*** derived ***cytokine*** inducing peptide SEQ ID
12.

L5 ANSWER 122 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB72256 peptide DGENE
TI Inducing a ***cytokine*** and modulating an immune response, useful
for treating central nervous system diseases and bacterial and viral
infections, comprises administering ***colostrinin*** as an
immunological regulator -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001011937 A2 20010222 50p
AI WO 2000-US22818 20000817
PRAI US 1999-149311 19990817
DT Patent
LA English
OS 2001-202804 [20]
DESC ***Colostrinin*** derived ***cytokine*** inducing peptide SEQ ID
11.

L5 ANSWER 123 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB72255 peptide DGENE
TI Inducing a ***cytokine*** and modulating an immune response, useful
for treating central nervous system diseases and bacterial and viral
infections, comprises administering ***colostrinin*** as an
immunological regulator -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001011937 A2 20010222 50p
AI WO 2000-US22818 20000817
PRAI US 1999-149311 19990817
DT Patent
LA English
OS 2001-202804 [20]
DESC ***Colostrinin*** derived ***cytokine*** inducing peptide SEQ ID
10.

L5 ANSWER 124 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB72254 peptide DGENE
TI Inducing a ***cytokine*** and modulating an immune response, useful
for treating central nervous system diseases and bacterial and viral
infections, comprises administering ***colostrinin*** as an
immunological regulator -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001011937 A2 20010222 50p
AI WO 2000-US22818 20000817
PRAI US 1999-149311 19990817

DT Patent
LA English
OS 2001-202804 [20]
DESC ***Colostrinin*** derived ***cytokine*** inducing peptide SEQ ID
9.

L5 ANSWER 125 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB72253 peptide DGENE
TI Inducing a ***cytokine*** and modulating an immune response, useful
for treating central nervous system diseases and bacterial and viral
infections, comprises administering ***colostrinin*** as an
immunological regulator -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001011937 A2 20010222 50p
AI WO 2000-US22818 20000817
PRAI US 1999-149311 19990817
DT Patent
LA English
OS 2001-202804 [20]
DESC ***Colostrinin*** derived ***cytokine*** inducing peptide SEQ ID
8.

L5 ANSWER 126 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB72252 peptide DGENE
TI Inducing a ***cytokine*** and modulating an immune response, useful
for treating central nervous system diseases and bacterial and viral
infections, comprises administering ***colostrinin*** as an
immunological regulator -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001011937 A2 20010222 50p
AI WO 2000-US22818 20000817
PRAI US 1999-149311 19990817
DT Patent
LA English
OS 2001-202804 [20]
DESC ***Colostrinin*** derived ***cytokine*** inducing peptide SEQ ID
7.

L5 ANSWER 127 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB72251 peptide DGENE
TI Inducing a ***cytokine*** and modulating an immune response, useful
for treating central nervous system diseases and bacterial and viral
infections, comprises administering ***colostrinin*** as an
immunological regulator -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001011937 A2 20010222 50p
AI WO 2000-US22818 20000817
PRAI US 1999-149311 19990817
DT Patent
LA English
OS 2001-202804 [20]
DESC ***Colostrinin*** derived ***cytokine*** inducing peptide SEQ ID
6.

L5 ANSWER 128 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB72250 peptide DGENE
TI Inducing a ***cytokine*** and modulating an immune response, useful
for treating central nervous system diseases and bacterial and viral
infections, comprises administering ***colostrinin*** as an
immunological regulator -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001011937 A2 20010222 50p
AI WO 2000-US22818 20000817
PRAI US 1999-149311 19990817
DT Patent
LA English
OS 2001-202804 [20]
DESC ***Colostrinin*** derived ***cytokine*** inducing peptide SEQ ID

5.

L5 ANSWER 129 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB72249 peptide DGENE
TI Inducing a ***cytokine*** and modulating an immune response, useful
for treating central nervous system diseases and bacterial and viral
infections, comprises administering ***colostrinin*** as an
immunological regulator -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001011937 A2 20010222 50p
AI WO 2000-US22818 20000817
PRAI US 1999-149311 19990817
DT Patent
LA English
OS 2001-202804 [20]
DESC ***Colostrinin*** derived ***cytokine*** inducing peptide SEQ ID
4.

L5 ANSWER 130 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB72248 peptide DGENE
TI Inducing a ***cytokine*** and modulating an immune response, useful
for treating central nervous system diseases and bacterial and viral
infections, comprises administering ***colostrinin*** as an
immunological regulator -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001011937 A2 20010222 50p
AI WO 2000-US22818 20000817
PRAI US 1999-149311 19990817
DT Patent
LA English
OS 2001-202804 [20]
DESC ***Colostrinin*** derived ***cytokine*** inducing peptide SEQ ID
3.

L5 ANSWER 131 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB72247 peptide DGENE
TI Inducing a ***cytokine*** and modulating an immune response, useful
for treating central nervous system diseases and bacterial and viral
infections, comprises administering ***colostrinin*** as an
immunological regulator -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001011937 A2 20010222 50p
AI WO 2000-US22818 20000817
PRAI US 1999-149311 19990817
DT Patent
LA English
OS 2001-202804 [20]
DESC ***Colostrinin*** derived ***cytokine*** inducing peptide SEQ ID
2.

L5 ANSWER 132 OF 134 DGENE COPYRIGHT 2004 THOMSON DERWENT on STN
AN AAB72246 peptide DGENE
TI Inducing a ***cytokine*** and modulating an immune response, useful
for treating central nervous system diseases and bacterial and viral
infections, comprises administering ***colostrinin*** as an
immunological regulator -
IN Stanton G J; Hughes T K; Boldogh I; Georgiades J
PA (TEXA) UNIV TEXAS SYSTEM.
(REGE-N) REGEN THERAPEUTICS PLC.
PI WO 2001011937 A2 20010222 50p
AI WO 2000-US22818 20000817
PRAI US 1999-149311 19990817
DT Patent
LA English
OS 2001-202804 [20]
DESC ***Colostrinin*** derived ***cytokine*** inducing peptide SEQ ID
1.

L5 ANSWER 133 OF 134 IMSRESEARCH COPYRIGHT 2004 IMSWORLD on STN

ACCESSION NUMBER: 2000:177 IMSRESEARCH
SOURCE: R&D Focus, (15 Jul 2002)
TRADE NAME: ***COLOSTRININ***
CHEMICAL NAME: unspecified
CAS REGISTRY NO.: 252266-11-8
STRUCTURE:

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

DERIVATIVE(S): 252266-11-8 ***colostrinin***
CLASSIFICATION: N7D9 All Other Anti-Alzheimer Products
HIGHEST DEV. PHASE: Phase II (40)

COMPANY INFORMATION:

Type	Company	Nationality
Originator	ReGen Therapeutics	United Kingdom

L5 ANSWER 134 OF 134 PHAR COPYRIGHT 2004 PJB on STN
AN 17177 PHAR
DN 028382
CN ***Colostrinin***
CN RG-010
CN ***Colostrinin*** (CAS)
RN 252266-11-8
STA Active

CO

Type	Company Name (Country)	Development Status
Originator	ReGen Therapeutics (United Kingdom)	Phase II Clinical Trial
Licensee	Rentschler (Germany)	Phase II Clinical Trial

PI WO 9965329

PRAI GB 19980616

SO Pharmaprojects. PJB Publications Ltd., Richmond, Surrey, UK
TX ***Colostrinin*** is a ***cytokine*** inducer isolated from sheep's milk, under development by ReGen Therapeutics for the treatment of Alzheimer's disease (AD). It has been isolated from ***colostrum***, which has immunomodulatory properties. It may also be effective in the treatment of dementia and hepatitis-B and cancer (Biotherapy, 1998, 11, 27; Scrip, 1998, 2380, 11; Regen, AGM, Jun 2003). Marketing Rentschler is supervising clinical trials in Poland and will conduct Phase II trials in Germany. It will also be responsible for submitting registration applications in Poland and Europe. Clinical Phase IIA European dose-ranging Phase IIb/III trial, including patients with early-stage Alzheimer's disease, was expected in the 3rd qtr of 2002 (not started as of Jul 2003) (Scrip Daily Online, 8 Jul 2002, S00762244; Direct communication, ReGen, 25 Nov 2002; Wall Street Transcript, Regen, May 2003). In a completed 6-centre placebo-controlled Phase II clinical trial in Poland in 106 patients with mild-to-moderate AD, ***Colostrinin*** was reported to have failed to show a significant treatment effect; however, further analysis of interim data at 15wk showed that it did meet its primary endpoint of significant treatment effect as measured by ADAS-cog, with 40% of patients showing benefit, and showed statistical significance in IADL. At 30wk, 33% of patients continued to benefit, and there were no drug-related serious adverse events or safety concerns. Best results were seen in patients with mild symptoms (Scrip Daily Online, 25 Mar 2002, S00749096 and 8 Jul 2002, S00762244). In a double-blind, placebo-controlled trial of ovine ***Colostrinin*** in 47 AD patients in Poland, 11/16 patients treated with ***Colostrinin*** improved and 5 stabilized after 1yr cf selenium and placebo groups, in which there were no improvements, and 3/16 and 11/15 patients stabilized, respectively. In a 12mth follow up of ***Colostrinin*** - and selenium-treated patients, 13/16 and 1/16 stabilized, respectively. After 2yr, average MMSE scores were 2.7 points higher and 5.2 points lower, respectively. Side-effects included anxiety, stimulation, insomnia and tiredness (Company prospectus, ReGen, Oct 1998). Preclinical screening for anticancer activity is planned (Regen, AGM, Jun 2003). 3 UK patents have been granted (Wall Street Transcript, Regen, May 2003). Licensing ReGen Therapeutics is looking for a partner to conduct Phase IIb trials (Scrip Daily Online, 8 Jul

2002, S00762244). Updated by AZ on 16/7/2003.

DSTA World: Phase II Clinical Trial

Argentina: Available for Licensing

Australia: Available for Licensing

Austria: Available for Licensing

Belgium: Available for Licensing

Brazil: Available for Licensing

Canada: Available for Licensing

Chile: Available for Licensing

China: Available for Licensing

Colombia: Available for Licensing

Denmark: Available for Licensing

Finland: Available for Licensing

France: Available for Licensing

Germany: Available for Licensing

Greece: Available for Licensing

Hong Kong: Available for Licensing

India: Available for Licensing

Ireland: Available for Licensing

Israel: Available for Licensing

Italy: Available for Licensing

Japan: Available for Licensing

Luxembourg: Available for Licensing

Malaysia: Available for Licensing

Mexico: Available for Licensing

Netherlands: Available for Licensing

Norway: Available for Licensing

New Zealand: Available for Licensing

Peru: Available for Licensing

Philippines: Available for Licensing

Portugal: Available for Licensing

Russian Federation: Available for Licensing

South Africa: Available for Licensing

Korea, Republic of: Available for Licensing

Spain: Available for Licensing

Sweden: Available for Licensing

Switzerland: Available for Licensing

Thailand: Available for Licensing

Turkey: Available for Licensing

United Kingdom: Preclinical; Available for Licensing

United States: Available for Licensing

Venezuela: Available for Licensing

CC N6D Cognition enhancer

J5Z Antiviral, other

K6Z Anticancer, other

CT Indication: Alzheimer's disease

ORGM ***Np*** -A (Natural product, animal)

RTE A-PO (Alimentary, po)

RDAT 20030716 RNTE ##Act##New Therapeutic Activity Anticancer, other (K6Z)

20020325 ##Est##Status changed Phase II Clinical Trial

20011213 ##Est##Licensing Opportunity Worldwide

19981030 ##Est##New Product

NRAT 6:Novelty Rating - Leading Compound

MRAT 2:Market Rating - US\$ 501-2000 million

SRAT 4:Speed Rating - Faster than Average

TRAT 12:Total Rating - Total Rating

PHCD IM-AG; Immunostimulant; Physiological, Hormonal, Immunostimulant; Immunogenic agent; P-H-IM-AG.

PHCD P; P-AG; P-H; P-H-AG; P-H-IM; P-H-IM-AG; H; H-AG; H-IM; H-IM-AG; IM; IM-AG.

LN

Therapy (CC)	Pharmacology (PHCD)	Status (DSTC)
N6D	IM-AG	C2
J5Z	IM-AG	P
K6Z	UN	P

LCDAT 20030716: AZ : Anticancer potential reported

STN INTERNATIONAL LOGOFF AT 15:31:00 ON 08 SEP 2004